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Abstract 
Intravenous tranexamic acid (TEA) is used in total hip arthroplasty (THA) to reduce 
blood loss.  Concern of increased thromboembolic risk has prompted the search for 
treatment alternatives.  The Tranexamic Acid Comparison in Hip Replacement (TeACH-
R) trial is a prospective randomized controlled trial comparing the efficacy of intravenous 
and topical TEA in reducing perioperative blood loss.  For interim data analysis, 52 of the 
planned 144 participants had completed the initial phase of the TeACH-R trial.  No 
significant differences were identified between the intravenous and topical TEA 
treatment arms for delta-hemoglobin (ΔHgb; 34.81±13.78 vs. 35.65±15.54 mg/dL; 
p=0.840), calculated blood loss (1548±509 vs. 1521±693 mL; p=0.873), or length of stay 
(55.0±11.44 vs. 54.5±20.1 hours; p=0.912).  No participant required a blood transfusion 
or had a thromboembolic event postoperatively.  Promising initial results support the use 
of topical TEA in THA, although therapeutic decisions should be made only once all data 
has been analyzed. 
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1 Introduction 
 
Blood conservation plays a very important role in the care of a patient with lower 
extremity joint replacement. The procedure mandates consideration as major orthopaedic 
surgery, where a significant amount of blood loss is expected both during and after 
surgery.  Tranexamic acid (TEA), a drug used to reduce perioperative blood loss, has 
been touted as a valuable adjunct to many perioperative blood conservation protocols.  
However, some concern remains over the efficacy and safety of the drug in hip 
replacement surgery.  This thesis will outline the development and results of a 
prospective randomized clinical trial (RCT), the TeACH-R trial.  The primary goal of this 
trial is to assess the comparative efficacy of TEA administered via two distinct routes, 
topical and intravenous, in decreasing blood loss after total hip arthroplasty (THA).  The 
following chapter outlines important clinical considerations leading to the development 
of the TeACH-R trial. 
 
1.1 Osteoarthritis 
Osteoarthritis (OA) is characterized as progressive degenerative change resulting in 
articular cartilage loss within a joint.  Cartilage erosion results from altered joint motion. 
In the lower extremity, the larger weight-bearing joints (the hip and knee) are affected 
more often than the smaller joints of the foot and ankle.  Osteoarthritis results in full 
thickness, complete articular cartilage loss, with changes extending to the subchondral 
bone.  Reactive osteophytes and bony sclerosis cause symptoms of stiffness, 
impingement and pain with weight bearing.  Soft-tissue structures are also affected by 
changes within the bony architecture.  Chronic inflammatory changes within the 
synovium cause hypertrophy, in addition to ligamentous laxity and muscle weakness 
resultant from disuse and altered biomechanical forces within the joint.1 
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The etiology of osteoarthritis is multifactorial, including both genetic and environmental 
influences.  Any joint in the body can be affected.  A number of pathologic and anatomic 
changes can lead to osteoarthritic changes.  Although most commonly presenting in 
idiopathic fashion without any identifiable cause (primary osteoarthritis), trauma, 
osteonecrosis or congenital disorders are all secondary causes that can predictably lead to 
degenerative changes.  Typically, the disease presents in middle age, although it can be 
earlier if secondary causes are suspected.  Known risk factors for the development of hip 
and knee osteoarthritis include advanced age, obesity, previous trauma or deformity in 
the affected joint, and joint instability1.  Pain and stiffness are the most frequent clinical 
symptoms expressed by sufferers of the disease.  Loss of active and passive range of 
motion at the affected joint is the most relevant clinical sign.  Radiographically, the 
disease is defined by progressive joint space loss, often in association with osteophytosis, 
sclerosis along the joint line, and subchondral cyst formation.  The complete clinical 
picture, in association with radiographic findings, determines the need for treatment. 
A number of non-operative treatment options are available to the clinician treating 
patients suffering with arthritis.  Although the principles of osteoarthritis treatment are 
generalizable to almost any joint, sufferers of lower extremity knee and hip osteoarthritis 
deserve special consideration as weight-bearing joints.  Conservative options attempt to 
offload the affected joint, or compartment within the joint.  These include activity 
modification, weight loss, and functional bracing to compensate for altered force vectors 
acting at the level of the joint.  Furthermore, supplementing with non-invasive 
pharmacologic agents helps in treating joint-related pain.  Anti-inflammatories, including 
non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen, are mainstays in 
the non-operative management of osteoarthritis with reliable therapeutic efficacy and 
favorable side effect profile.  Corticosteroid injections into the affected joint can also 
provide a significant amount of pain relief.  It is important, however, to realize that all 
aforementioned treatment modalities are focused on management of pain-related 
symptomatology.  Although these help in delaying the need for operative intervention, 
they do not halt the progression of disease.  A high percentage of patients treated 
conservatively for hip and knee osteoarthritis eventually progress to joint replacement 
surgery due to incapacitating pain and disability unresponsive to conservative therapy.  In 
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Ontario, the burden of disease is significant:  health care costs are 2 to 3 times higher, and 
quality-of-life is consistently rated 10 to 25 percent lower in individuals with 
osteoarthritis.2  Worldwide, it is estimated that 10 percent of all people over the age of 60 
years suffer from OA.  It has proven difficult to reliably assess the proportion of people 
with OA who progress to THA, but there is evidence that the prevalence of OA does 
increase with age3.  With the aging population, the economic and social burden of 
osteoarthritis is ever increasing. 
 
1.2 Lower Extremity Arthroplasty 
In the medical nomenclature, joint replacement surgery is termed arthroplasty:  arthr(o)- 
defined as “relating to a joint” and –plasty, of Greek origin “to form”4.  Practically, 
arthroplasty refers to the operative reconstruction or replacement of a diseased joint.  The 
term arthroplasty is all encompassing, often used to denote a variety of joint-related 
reconstructive procedures. It is helpful to consider that all joints have two articulating 
cartilaginous surfaces.  Joint reconstruction implies resurfacing or replacing both 
articulating surfaces of a joint.  Often, like in THA, there is resection of supportive bone 
mass along with the articular surface prior to implantation of the prosthesis. 
Three bony articulations in the lower extremity are prone to degenerative changes 
requiring reconstructive surgery: the ankle (tibio-talar) joint, the knee (tibio-femoral and 
patellofemoral) joint and the hip (femoroacetabular) joint.  Severe degenerative changes, 
in association with debilitating symptoms and decreased quality of life, are indications 
for joint replacement.  The focus of this dissertation is on reconstruction of the hip joint.  
The surgical procedure, as described in the following section, involves complete 
resection of the femoral head and neck, with concomitant resurfacing of the acetabular 
articular surface. 
1.2.1 Total Hip Arthroplasty 
Primary total hip arthroplasty continues to help a great number of individuals who suffer 
from OA.  The 2014 Canadian Joint Replacement Registry Annual Report states that 
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24,515 primary total hip replacements were performed across Canada in 2012-135.  As 
can be seen in Figure 1.1, the vast majority of primary THA performed in Canada are for 
a diagnosis of primary osteoarthritis. 
 
Figure 1.1: Most Responsible Diagnosis for Primary Total Hip Replacement, fiscal 
year 2012-2013. (Reproduced with permission from the Canadian Joint Replacement 
Registry 2014 Annual Report, www.cihi.ca/cjrr) 
 
Success of THA can be defined in many ways.  From the patient perspective, satisfaction 
is usually excellent after primary THA if the indication for surgery is for the relief of pain 
associated with osteoarthritic changes within the joint.  Quality of life reliably improves 
after THA.  From the standpoint of implant longevity, survivorship of most implant 
systems is approximately 95% at 10-year follow-up6, 7.  Overall, THA offers those with 
end-stage degenerative hip disease a viable surgical option with predictably good 
outcomes.  However, it is considered a major intervention, putting the patient at risk both 
during the procedure and throughout the postoperative course.  Although the expected 
benefits are significant, careful patient selection and preoperative medical optimization is 
paramount in order to gain the most benefit with minimal risk. 
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1.2.1.1 Surgical Technique 
The modern age of THA comes after many fundamental changes in implant design and 
materials engineering.  However, the surgical technique remains similar to the low-
friction arthroplasty described by Sir John Charnley in the 19628, 9. 
The bones of the hip joint lie deep in the area of the pelvis beneath a number of important 
soft tissue structures, including muscles, tendons, nerves and arteries.  There are many 
described surgical approaches to exposing the femoral head and acetabulum safely.  The 
three main surgical approaches commonly used in North America are the modified direct 
lateral (Hardinge) approach, the posterior (Southern-Moore) approach and the direct 
anterior (Smith-Peterson or Heuter) approach.  At London Health Sciences Center, 
University Hospital (LHSC-UH), the most common approach is the modified direct 
lateral approach.  In his original publication, Dr. Kevin Hardinge describes the approach 
with the patient laying supine on the operating table10; the modified Hardinge approach 
uses lateral decubitus positioning to aid with visualization.  Proponents of using this 
approach cite adequate operative exposure, with a very low rate of prosthetic dislocation 
of the implant in the postoperative period.  Disadvantages are related to the trans-
muscular nature of the approach and limited visualization of the acetabulum.  
Consequently, there is potential to increase surgical bleeding as a result of injury to the 
perforating arteries located within the muscular layers of the upper thigh, as described in 
Section 1.3.1. 
Graphical representation of the modified Hardinge surgical approach to the hip joint is 
outlined in Figure 1.2.  Starting with a lateral skin incision centered over the greater 
trochanter, sharp dissection proceeds through the subcutaneous fat layer to reveal the 
fascia of the gluteal musculature, thickening distally to form the iliotibial (IT) band.  A 
longitudinal incision through the IT band and fascia allows identification of the gluteus 
medius musculature overlying the anterolateral aspect of the proximal femur.  In the next 
tissue layer, a split in the gluteus medius muscle belly in line with its muscle fibers 
overlying the femoral neck allows identification of gluteus minimus.  An incision is made 
through the tendinous portion of gluteus minimus and the capsule overlying the femoral 
neck.  Reflection of the gluteus medius and vastus lateralis off the anterior aspect of the 
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femur allows visualization of the entire proximal femur.  After release of periarticular 
structures, surgical dislocation of the femoral head allows enough visualization to 
properly landmark the femoral neck osteotomy site approximately one centimeter above 
the lesser trochanter.  Once the osteotomy is completed, the femoral head is excised and 
the shaft of the proximal femur translated posterolaterally.  The floor of the acetabulum is 
then visible, and preparation of the femoral and acetabular surfaces for implantation of 
the prosthesis can proceed. 
 
 
 
Figure 1.2: Modified Direct Lateral (Hardinge) Approach to the Hip Joint.  After the 
skin incision, an incision is made through the IT band and gluteal fascia (A).  The gluteus 
medius is divided, leaving a tendinous cuff attachment to the greater trochanter (B), 
exposing the gluteus minimus and capsular tissue layers (C).  Further incision through the 
gluteus minimus and capsule, followed by elevation of a muscular flap off the anterior 
proximal femur, allows dislocation of the femoral head and preparation for the femoral 
neck osteotomy (D). (Reproduced with permission and copyright © of the British 
Editorial Society of Bone and Joint Surgery from Hardinge, K. J Bone Joint Surg Br 
1982; 64-B(1): 17-19) 
A B  
C D  
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Although cement fixation of femoral and acetabular components was common practice in 
the past, and still has a role in primary THA for hosts with poor capacity for bony 
ingrowth, cementless (press-fit) fixation is the popular choice for the majority of North 
American surgeons.  The sequence of preparation of the femoral neck osteotomy and 
acetabular surfaces for implantation of cementless implants is surgeon-dependent.  For 
the acetabulum, all soft tissues, including the labrum, are excised to reveal the entire 
articular surface.  Reaming of the acetabulum, a process of excising degenerative 
acetabular cartilage and sclerotic bone using sequential reamers of increasing diameter, 
allows the creation of a bed and surrounding rim for fixation of the press-fit shell.  This 
shell will hold a highly cross-linked polyethylene liner, the acetabular bearing surface.  
On the femoral side, the intramedullary canal is first identified, and preparation of the 
canal allows for sizing of the final prosthesis.  Rotational and axial stability of the 
femoral implant is due to a secure fit of the prosthesis within the proximal femur.  
Modern implants have a modular femoral head component sitting on the femoral stem at 
the head-neck junction.  Trialing of various femoral head lengths allows for appropriate 
sizing.  This critical step is necessary in order to maintain appropriate implant stability, 
keeping in mind the patient’s soft tissue tension and leg length.  Once the final 
components are selected, implantation ensues, with subsequent closure of all tissue layers 
to complete the operative procedure. 
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Figure 1.3: Modern Cementless Total Hip Implant (in situ). The femoral component 
is press-fit into the proximal metadiaphyseal portion of the intramedullary canal.  The 
modular femoral head component articulates with the liner.  The acetabular shell is firmly 
seated into the reamed acetabulum. (Reproduced with permission and copyright © from 
Pivec, R et al. Lancet 2012; 380: 1768-77) 
 
1.3 Blood Loss During and After Total Hip Arthroplasty 
Despite the best intentions of the treating orthopaedic surgeon, complications are 
occasionally seen after THA.  Clinically significant blood loss often presents insidiously.  
The soft tissues in and around the hip, notably the significant adiposity in the subdermal 
layers of the thigh, make the THA patient vulnerable to a significant amount of 
unrecognized blood loss during and after the operative procedure.  Unlike in total knee 
arthroplasty (TKA), a tourniquet cannot be applied prior the operation given the proximal 
nature of the skin incision.  Best efforts to maintain intraoperative hemostasis are taken 
by the treating surgeon and anesthesiologist, in order to reduce bleeding into the 
postoperative period. 
1.3.1 Sources of Blood Loss During Total Hip Arthroplasty 
Importantly, bone ends that have been osteotomized have a propensity for continued 
bleeding into the postoperative period.  Unfortunately, the surgeon has limited options for 
9 
 
dealing with bleeding from vessels contained within bone, as neither electro-cautery nor 
suture ligation is effective at arresting the persistent ooze emanating from cancellous 
bone.  Both the femoral intramedullary canal and the periacetabular region contain a 
significant amount of cancellous bone.  In THA, bony blood loss arises from both the 
femoral neck osteotomy site and subchondral bone on the acetabular surface after the 
latter has been reamed.  Although implantation of final components in press-fit fashion 
does provide a mechanism for local tamponade of bleeding bone, in the absence of a 
competent clotting cascade continued hemorrhage may be significant enough to require 
transfusion of packed red blood cells, either autogenic or allogeneic.  Moreover, the 
direct lateral approach, trans-muscular by definition, does place the perforating 
intramuscular branches of the femoral arterial system at risk of injury.  Ruptured 
intramuscular arteries can retract into the muscle bed, making it particularly difficult to 
grasp and ligate the ends of the injured vessel intraoperatively. The above can occur 
without any overt external blood loss or hematoma formed in the visible superficial 
tissues surrounding the hip joint.  It is this slower, persistent bleeding that is targeted with 
the administration of antifibrinolytic agents in the perioperative period, as described in 
Section 1.4 and 1.5. 
Thankfully, vascular injury to the main branches of the iliac, femoral or obturator 
vascular system remains a rare complication of THA, estimated at 0.25%11, usually as a 
result of aggressive retractor placement in the antero-superior acetabulum and proximal 
femur.  The placement of acetabular screws is also a risk factor for intraoperative 
bleeding given the relative proximity to major blood vessels, as seen in Figure 1.5.  Deep 
drill or screw penetration can lead to vascular penetration, thrombosis, and significant 
amounts of intra-pelvic blood loss.  Although rare, this does represent another source of 
blood loss in THA.  Antifibrinolytics do not target these causes of massive intraoperative 
hemorrhage. 
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A  
B  
Figure 1.4: Common Femoral Artery and Major Branches Around the Hip.  
Proximal (A) and distal (B) extension of the external iliac and common femoral artery is 
visualized above.  Important anatomic relationships of relevance to the surgical approach 
for the hip are noted.  The smaller branches of the femoral arterial system are at risk 
during the direct lateral surgical approach. (Reproduced from Nachbur, B et al. CORR 
1979; 141: 122-132) 
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Figure 1.5: Relationship of Pelvic Vascular Structures to Surface Acetabular 
Landmarks.  For acetabular screw placement, the “safe zone” corresponds to the 
postero-superior quadrant of the acetabulum, where the only vascular risk is the superior 
gluteal artery.  “Danger zones” correspond to the antero-superior and antero-inferior 
quadrants, where the external iliac vessels and obturator pedicle lie in close proximity to 
the acetabular fossa.  (Reproduced with permission and copyright © from Springer, 
Feugier, P et al. Surg Radiol Anat 1997; 19(2): 85-90) 
 
1.3.2 Physiologic Response to Surgical Blood Loss 
The human response to blood loss is predictable.  If hypovolemia due to hemorrhage is 
significant, the initial response is to maintain cardiac output.  Until hypovolemia is 
corrected, a decrease in cardiac preload results in a decrease in stroke volume.  Heart rate 
increases proportionally to compensate for the lack of intravascular volume, and systemic 
vascular resistance decreases to reduce cardiac afterload.  Although transport of oxygen 
is presumed to be negatively affected by an acute loss of red blood cell mass, Weiskopf et 
al showed that in healthy conscious volunteers at rest, a drop in hemoglobin to 50 mg/dL 
did not result in a significant drop in oxygen carrying capacity or clinically significant 
tissue hypoxia12.  Although these represent important findings, the stress of major 
Anterior Posterior 
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orthopaedic surgery in the elderly arthroplasty patient is likely to produce significant 
biochemical changes affecting that individual’s physiologic capacity to respond to acute 
or subacute blood loss. 
The coagulation and fibrinolytic systems are the keystones of the human body’s inherent 
hemostatic mechanism.  Both pathways are termed cascades because of the hierarchical 
activation of serine proteases.  One receptor-ligand interaction triggers a coordinated set 
of downstream reactions, eventually leading to a stable clot.  The dynamic interplay 
between coagulation and fibrinolysis attempts to seal a bleeding vessel, while 
maintaining enough patency of the vascular lumen to allow nutrient delivery to 
downstream tissues.  Coagulation, as the name implies, performs the former function and 
occurs by interacting closely with the initial platelet plug to form a stable complex of 
macromolecules, or clot, over bleeding vessels.  Fibrin, the active form of the pro-peptide 
fibrinogen, plays an important role in the process of coagulation, forming an intricate 
network of cross-linked fibers within the platelet plug to form an insoluble clot.   On the 
other hand, fibrinolysis acts to break down this clot in order to maintain a patent 
intravascular lumen.  Here, plasmin plays a key role in breaking apart the cross-linked 
fibrin.  These cascades are outlined in Figure 1.6.  
Although the intrinsic pathway is an important contributor to coagulation, the extrinsic, 
or tissue factor-mediated coagulation pathway is predominantly responsible for the 
initiation and propagation of the coagulation cascade during and after surgical trauma.  
Tissue factor (TF), a macromolecule present in the subendothelial layer of blood vessels 
and in the extracellular environment, is not exposed to flowing blood unless there is 
vascular injury causing intimal damage.  TF is the receptor for factor VII (FVII), the 
latter flowing freely in the bloodstream.  FVII interact with TF only if TF becomes 
exposed to flowing blood; upon binding, FVII becomes activated (FVIIa), and 
subsequently interacts with factor X (FX).  FX, once activated, cleaves prothrombin to 
thrombin.  Thrombin, in turn, cleaves fibrinogen to fibrin, the active monomer 
contributing to a highly cross-linked mesh able to stabilize the initial platelet plug.  
Thrombin also catalyzes the conversion of factor XIII (FXIII) to its active form (FXIIIa), 
which is a necessary cofactor for cross-linking of fibrin monomers13. 
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Figure 1.6: Overview of the Coagulation and Fibrinolytic Cascades.  Tissue Factor is 
released when a blood vessel is injured.  The subsequent cascade of serine proteases leads 
to the conversion of prothrombin to thrombin, which converts fibrinogen to fibrin.  Under 
the influence of Factor XIIIa, fibrin monomers get cross-linked.  Fibrinolysis occurs upon 
binding of tissue plasminogen activator (tPA) to plasminogen, with subsequent 
conversion to plasmin. Plasmin then degrades the fibrin clot, with formation of fibrin 
degradation products. (Reproduced from McGilvray, ID and Rotstein, OD. Surgical 
Treatment: Evidence-Based and Problem-Oriented.  2001.  
http://www.ncbi.nlm.nih.gov/books/NBK6959/) 
 
Fibrinolysis is the counter-regulatory process that assures continued flow through the 
lumen of the bleeding vessel.  Plasminogen is the inactive precursor of plasmin, 
circulating in the bloodstream.  Conversion of plasminogen to its active form proceeds 
only once plasminogen binds to fibrin, where this zymogen adopts an open conformation.  
Only at this point is an activator, such as tissue plasminogen activator (tPA), able to bind 
the molecule and convert it to its active serine protease, plasmin.  Plasmin can then act to 
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cleave the fibrin cross-links, destabilizing the formed clot in order to ensure vessel 
patency14.  Fibrin degradation products (FDP) are formed upon cleavage of fibrin cross-
links. 
1.3.3 Hemostasis in Arthroplasty 
Total knee and total hip arthroplasty produce a significant amount of tissue trauma.  In 
TKA, postoperative hemostasis is largely influenced by the accelerated fibrinolytic 
reaction at time of tourniquet release15, 16.  The same is not seen in THA, as tourniquet 
application is not possible when operating on the hip joint.  Initiation of the coagulation 
cascade, with concurrent activation of the fibrinolytic system, begins from the time of 
initial of tissue trauma.  The surgeon is dependent on a number of surgical techniques to 
control blood loss in the surgical field during THA.  Suture ligation, electro-cautery and 
the application of synthetic sealant products and tissue glues are valuable tools available 
to the surgeon attempting to achieve intraoperative hemostasis.  Watertight closure 
techniques with the concomitant goal of decreasing dead space between tissue layers can 
also decrease the space available for collection of blood in the potential spaces around the 
hip joint. The anaesthesia team has a key role in identifying and treating surgical 
hypovolemia.  The administration of intravenous resuscitative fluids, vasoactive 
medications and the control of blood pressure contribute significantly to reducing 
intraoperative blood loss.  However, as mentioned in Section 1.3.1, not all sources of 
intra-operative blood loss are amenable to correction via these modalities. 
Bleeding in the postoperative period is further potentiated by the need for anticoagulation 
after lower extremity total joint arthroplasty.   Total hip and knee arthroplasty are 
considered procedures that carry a moderate-to-high risk of postoperative 
thromboembolic events.  A deep vein thrombus (DVT) can migrate proximally 
throughout the venous system to cause pulmonary emboli (PE), both considered major 
venous thromboembolic events (VTE).  If large enough in size, PEs can lodge in the 
pulmonary arterial tree, resulting in a ventilation-perfusion mismatch.  If the area of lung 
affected is large, or in the event of the dreaded saddle embolus blocking the confluence of 
the right and left pulmonary arteries, this can be a fatal complication of elective surgery. 
Commonly, a direct thrombin inhibitor such as rixaroxaban, or an agent in the low-
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molecular-weight heparin class such as dalteparin is indicated for the purpose of 
decreasing the incidence of these important, potentially life-threatening postoperative 
complications.  In respective guideline statements, the American College of Chest 
Physicians and the American Academy of Orthopaedic Surgeons both strongly endorse 
thromboembolic prophylaxis as standard of care after lower extremity total joint 
arthroplasty17, 18.  In a recent randomized clinical trial published in the New England 
Journal of Medicine, major VTE occurred in only 0.2% of 1595 participants receiving 
rivaroxaban, an absolute risk reduction of 1.7% when compared to the treatment group 
receiving enoxaparin, another oft-utilized thromboprophylactic agent19.  On the other 
hand, the incidence of asymptomatic DVT or PE is estimated at approximately 50% when 
prophylactic anticoagulation is not initiated in the postoperative period20.  The contrasting 
results of these studies emphasize the need for effective thromboprophylaxis after THA. 
Management of blood loss in arthroplasty is a significant challenge, not only because of 
difficulties in controlling the source of blood loss, but also because of a lack of 
therapeutic options in modulating the coagulation and fibrinolytic cascades to effectively 
decrease blood loss.  In attempts to stop bleeding, maintaining vessel patency and 
avoidance of dreaded thromboembolic complications are also critical factors to consider 
in the perioperative care of the arthroplasty patient.  Blood conservation protocols reflect 
these goals of treatment. 
 
1.4 Perioperative Blood Conservation 
1.4.1 Preoperative Anemia in the Total Hip Arthroplasty Patient 
The adverse effects of blood loss are complicated by the relatively high incidence of 
preoperative anemia in the arthroplasty patient population.  It is estimated that 
approximately 25 to 45 percent of patients proceeding to THA or TKA are anemic pre-
operatively21.  Preoperative use of NSAIDs causing subacute gastrointestinal blood loss 
and anemia of chronic disease are prevalent etiologies for anemia in the arthroplasty 
patient.  Preoperative anemia has been cited as a risk factor for postoperative infection, 
transfusion, and even mortality21.  In a landmark paper, Carson determined that “the 
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effect of blood loss on mortality was larger in patients with low preoperative hemoglobin 
than in those with a higher preoperative hemoglobin.”22 
 
The presence of concurrent medical comorbidities mandates a thorough preoperative 
medical review as a part of the evaluation of the perioperative evaluation for the 
arthroplasty patient.  Management of preoperative anemia, in particular, plays a large role 
in medical optimization prior to total joint arthroplasty.  As mentioned in Section 1.3.2, 
decreased oxygen carrying capacity from low red blood cell mass decreases the potential 
for aerobic metabolism in downstream tissues, increasing the risk for end-organ ischemia.  
Although this may not be a factor in young, healthy individuals, the typical elderly 
arthroplasty patient does not meet these criteria.  The heart is particularly vulnerable in 
this patient population.  The presence of ischemic heart disease, in addition to concurrent 
pharmacologic treatment with cardiogenic medications, decreases the intrinsic 
physiologic response to surgical stress. 
 
1.4.2 Risk of Perioperative Transfusion 
It is now understood that allogeneic transfusion for the treatment of anemia related to 
surgical blood loss should be avoided when possible.  In addition to cost and resource 
constraints, the current evidence shows an increased risk of surgical site, urinary tract and 
respiratory tract infections in patients that receive allogeneic blood in the postoperative 
period23-26.  Ongoing concerns regarding the safety of transfusing stored blood products 
have ushered in the use of restrictive transfusion algorithms for surgical patients, showing 
significant clinical benefit over the liberal transfusion of blood products in a number of 
high-quality studies in surgical and critically ill patients22, 27, 28.  A restrictive transfusion 
algorithm is in use at LHSC-UH; further details are provided in Chapter 3.5.3. 
1.4.3 Blood Conservation Modalities 
A multidisciplinary approach to blood conservation in total joint arthroplasty is 
paramount to optimal perioperative care of the arthroplasty patient. Although there exists 
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some heterogeneity in blood conservation protocols across centers, several common 
themes are present. 
Pharmacologic iron supplementation and the use of erythropoietin-stimulating agents 
(ESA) increase red cell mass prior to surgical intervention, with good efficacy and 
reasonable safety profiles21.  Both can have significant clinical benefits, especially if 
started over 3 weeks prior to surgery29.  Whereas iron supplementation has proven benefit 
with general ease of administration preoperatively, ESA can be a costly modality 
reserved for patients meeting strict diagnostic criteria.  Preoperative autologous blood 
transfusion, intraoperative cell salvage, and postoperative blood reinfusion strategies are 
moderately effective, and have been used as part of perioperative blood conservation 
protocols in the past.   However, these have decreased in popularity as a result of 
modalities that are less resource-intensive and of similar efficacy and safety30, 31.  A 
number of studies in both hip and knee arthroplasty have affirmed the clinical utility of 
antifibrinolytic agents, such as TEA, in reducing blood loss in the perioperative period.  
As evidenced in the following sections, these represent promising adjuncts to traditional 
blood conservation protocols, especially for the patient at risk of significant 
intraoperative blood loss. 
 
1.5 Antifibrinolytics 
The use of antifibrinolytic therapy in surgery has grown due to a number of inciting 
factors and events.  In recent years, the ever-increasing cost and incidence of transfusion-
related complications has ushered in widespread reluctance to the use of blood products 
in the perioperative setting.  Consequently, medical and surgical teams managing of the 
perioperative care of patients having surgical interventions with an elevated risk of blood 
loss have developed blood conservation protocols to decrease the reliance on allogeneic 
blood products for the treatment of surgical anemia.  Antifibrinolytics, such as TEA, 
epsilon-aminocaproic acid (EACA) and aprotinin, were first identified as useful adjuncts 
in cardiothoracic interventions, where a counter to the potent fibrinolysis-inducing effect 
of cardiopulmonary bypass was sought by surgeons and anaesthesiologists seeking better 
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control of perioperative bleeding.  After a number of high-quality studies showed good 
clinical effect with minimal risk to the patient32-34, orthopaedic surgeons began to 
institute antifibrinolytics prior to and during procedures carrying a significant risk of 
blood loss, lower extremity total joint arthroplasty included.  The following section 
provides an overview of the pharmacology inherent to antifibrinolytic therapy, and its 
role in the perioperative care of the arthroplasty patient. 
1.5.1 Lysine Analogues:  Tranexamic Acid and Epsilon-
Aminocaproic Acid 
Tranexamic acid and epsilon-aminocaproic acid comprise the lysine analogue class of 
antifibrinolytic agents.  They have identical mechanisms of action, with TEA displaying a 
six- to ten-fold increased affinity compared to the EACA moiety35, 36.  Owing to its high 
affinity and comparatively low cost, TEA has largely replaced EACA as the predominant 
lysine analogue used in major orthopaedic procedures. 
Lysine analogues prevent fibrinolysis.  The structural similarity to the amino acid lysine 
allows the drug to bind the lysine-binding site on plasminogen.  Under normal 
circumstances, plasminogen is a promoter of fibrinolysis when combined with tPA.  
Plasminogen subsequently gets converted to plasmin, with the active lysine-binding site 
on plasmin now able to interact with the active receptor on fibrin.  Plasmin can then 
break down cross-linked fibrin and dissolve insoluble mesh of fibrin holding the clot 
together.   TEA acts as a competitive inhibitor of plasminogen via action at this fibrin-
binding site.  Plasmin can no longer bind fibrin when TEA is bound to the lysine-binding 
site.  Fibrin remains cross-linked, stabilizing the formed clot and promoting local 
hemostasis (Figure 1.7). 
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Figure 1.7:  Mechanism of Action, Tranexamic Acid (and Epsilon-Aminocaproic 
Acid).  Due to structural similarities to lysine, both tranexamic acid and epsilon-
aminocaproic acid moieties competitively inhibit binding of fibrin to plasminogen via 
interaction at an active lysine-binding site.  Fibrinolysis is prevented, with concomitant 
stabilization of the fibrin clot.  (Reproduced with permission from Dunn, CJ and Goa, 
KL. Drugs 1999; 57: 1005-1032) 
 
The pharmacokinetic properties of the lysine analogues make this class of medication 
ideal for decreasing the short-lived intra-articular fibrinolytic response after lower 
extremity joint replacement surgery.  Both molecules rapidly diffuse across tissue planes, 
and are able to reach effective concentrations within the joint shortly after intravenous 
administration.  Studies in cardiac surgery have elucidated the pharmacokinetic and 
pharmacodynamic properties of intravenous TEA, sought after in attempts to find the 
safest and most effective dose. It has been determined that the distribution and 
elimination of TEA follows first-order kinetics, with a half-life of roughly 2 hours.  TEA 
is not bound to proteins in the systemic circulation, and is rapidly excreted in urine 
largely unchanged in chemical structure.  A serum concentration of 10-15 µg/mL 
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decreases fibrinolytic activity of plasmin by approximately 80%38.  Also, when 
administered via the topical or intra-articular routes, systemic absorption of TEA is 
reduced by approximately 70% of the equivalent intravenous dose39.  Because of renal 
elimination, dose adjustments are necessary in those with decreased kidney function, but 
not in those with hepatic impairment35, 36.  Other side effects, as well as local and 
systemic allergic reactions are rare complications of antifibrinolytic administration. 
1.5.2 Plasmin Inhibitors:  Aprotinin 
Aprotinin, a thrombin inhibitor derived from bovine lung tissue, has also been in total 
joint arthroplasty.  Its activity on the fibrinolytic cascade has yet to be fully elucidated, 
although it is postulated to exert most of its clinical effect indirectly by decreasing the 
activation of factor XII through an inhibitory effect on the kallikrein pathway.  The 
proteolytic activity of plasmin is also inhibited by aprotinin directly, although the 
mechanism is unclear40. 
In 2008, use of aprotinin was restricted in a number of countries, including both Canada 
and the United States, as a result of increased mortality when used in cardiac surgery.  
These results emanated from a large multi-center study, the Blood Conservation using 
Antifibrinolytics in a Randomized Trial (BART)41.  These same findings were not present 
when TEA was used for this same purpose.  Within the past two calendar years, the 
European Medicines Agency and Health Canada have reinstated aprotinin for use in 
cardiac surgery, but only in cases where an excessive amount of blood loss is expected.  
Given the increased cost as well as safety concerns related to use of aprotinin, it is no 
longer routinely used as an antifibrinolytic agent in orthopaedic surgery. 
 
1.6 Tranexamic Acid Administration in Total Hip Arthroplasty 
TEA is a versatile drug that has been used with therapeutic success in bleeding trauma 
patients42, gynecologic surgery, cardiac surgery43, 44, 33, 45, thoracic surgery34 and only 
more recently orthopaedic surgery.  Administration via the oral, topical, intra-articular 
and intravenous routes is described in each of these surgical fields.  As will be discussed 
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in Chapter 2, there is documented Level I evidence to support the use of TEA in both 
TKA and THA.  Although these procedures are inherently different in many ways, a 
review of the available evidence in TKA is essential to understand the rationale in the 
TeACH-R study design and the need to assess the clinical efficacy for intra-articular 
administration of TEA in THA. 
The comparative efficacy of intravenous and topical administration of TEA has never 
been assessed in patients undergoing THA.  TeACH-R is the short form for the study 
entitled Tranexamic Acid Comparison in Total Hip Replacement, a study developed at 
LHSC-UH powered to detect a clinically significant change in the hemoglobin drop after 
THA.  The purpose of the study is to perform a direct comparison of clinical efficacy 
between intravenous and topical administration of TEA, with the primary outcome 
measure of blood loss and drop in postoperative hemoglobin.  The standard of care at 
LHSC-UH, based predominantly on results of a 2010 retrospective review by Ralley and 
colleagues, is to administer a single dose of 20 mg/kg of TEA intravenously 10 minutes 
prior to skin incision for THA46.  This allows the solution to be infused completely before 
the start of the operation.  The drop in hemoglobin postoperatively was lessened, with a 
concomitant decrease in the rate of postoperative allogeneic blood transfusion.  However, 
an important study by Wong suggests that topical TEA administration in TKA has similar 
clinical benefit in terms of decreased blood loss and transfusion rate, with either a 1.5 
gram or 3 gram single-bolus dose administered prior to tourniquet desufflation.   In this 
study, plasma TEA levels drawn one hour after administration showed sub-therapeutic 
levels in the group receiving the 1.5 gram dose, indicating that even marginal plasma 
TEA levels can have good therapeutic effect in inhibiting the local fibrinolytic cascade 
without the risk that comes with elevated systemic load.  To the best of the investigators’ 
knowledge, a similar study has yet to be performed in THA, owing in large part to the 
lack of consistency in dosing and timing of administration in published studies examining 
TEA. 
Direct antifibrinolytic action on bleeding vessels and a decreased risk of arthroplasty-
related thromboembolic events (albeit theoretical) are potential advantages of 
administering TEA topically in THA.  The TeACH-R investigators decided to administer 
22 
 
TEA topically at the time of arthrotomy closure, as it provides a reproducible method of 
administering the medication without interfering with surgical time while maintaining 
therapeutic activity.  The goal is to target postoperative blood loss from intramuscular 
vessels and cancellous bone, in order to blunt the hemoglobin drop and reduce the need 
for transfusion of pRBCs.  By allowing the TEA solution to bathe the joint while the 
tissue layers are closed in succession, the drug is then given a significant of time to exert 
its clinical action.  A dose of 1.5 grams was chosen based on the results of previous 
studies showing no clinical benefit of a higher dose in total joint arthroplasty39.  Blood 
loss and complications in TeACH-R study participants receiving this topical regimen are 
compared to single-bolus intravenous TEA administration at 20 mg/kg, the standard of 
care at LHSC-UH.  Because the standard of care is an active agent with well-documented 
clinical efficacy, a placebo-controlled trial in this setting has significant ethical 
implications. 
We hypothesize that administering topical TEA at the time of arthrotomy closure will not 
show a significant drop in the postoperative hemoglobin or perioperative blood loss when 
compared to intravenous TEA administered prior to the start of THA. 
There is a significant body of evidence supporting the use of TEA over no antifibrinolytic 
therapy, whether it is administered intravenously or topically47.  Proceeding with this 
study is part of the process of determining which is the most effective therapeutic 
regimen for administering TEA in THA.  Not only will our results go a long way in 
optimizing blood conservation protocols for patients proceeding to THA at LHSC-UH, 
but this study will also allow others in the field to build on the current available 
knowledge base in order to gain the most clinical benefit of TEA while minimizing 
perioperative risk. 
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2 Literature Review 
 
The following provides a brief overview of the relevant studies that have contributed to 
the gradual increase in popularity of TEA as a valuable adjunct in perioperative blood 
conservation programs.  Only recently have appropriately powered clinical trials 
demonstrated clear benefit of administering TEA in both TKA and THA, regardless of 
whether the route of administration is intravenous (IV), intra-articular (IA) or topical. 
 
2.1 Intravenous Tranexamic Acid in Total Knee Arthroplasty 
Evidence supporting the use of TEA in lower extremity total joint arthroplasty first 
appeared in a small series of patients needing TKA, where Benoni et al showed that TEA 
would provide an effective counter to the hyperfibrinolytic reaction seen after tourniquet 
desufflation in TKA15.  Ease of use and ability to administer serial doses of TEA were 
seen as advantages to administering the drug intravenously, although early reluctance to 
implementing TEA came from clinical studies that questioned the earlier claims of 
efficacy in decreasing blood loss after knee replacement surgery.  Good et al assessed the 
effect of TEA on hidden blood loss in TKA using a 10 mg/kg dose of IV TEA given just 
before tourniquet release, concluding that the hemostatic agent reduced total blood loss 
and drain volume, but showed no discernable effect on reduction of hidden blood loss48.  
Larger, more recent studies have shown more promising results.  A European clinical 
trial provided Level I evidence supporting the clinical and economical benefits of IV 
TEA in TKA, stating that use of TEA in the perioperative setting reduced blood loss by 
approximately 600 mL compared to placebo, making postoperative autologous reinfusion 
unnecessary and cost-prohibitive when a restrictive transfusion protocol is enforced 
concurrently30.  In comparison to other traditional methods of intraoperative blood 
conservation, when two separate formulations of fibrin glue were compared to IV 
administration of TEA in a recent clinical trial, TEA was deemed to be the only effective 
agent in decreasing drain and calculated blood loss49. 
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Although a general consensus exists supporting the benefits of IV TEA in TKA, 
significant heterogeneity exists between studies with regards to treatment regimens and 
outcome measures, making it difficult to reliably assess the true clinical effect of 
adjunctive antifibrinolytic therapy.  The ideal protocol with regards to dosing and timing 
of administration has yet to be fully elucidated, although recent evidence suggests 
improved control of postoperative blood loss with serial administration of TEA during 
the perioperative period.  In order to clarify this conflicting data, Maniar and colleagues 
designed a trial comparing four separate modes of TEA administration. In their study, 
patients receiving preoperative, intraoperative and postoperative administration of IV 
TEA at 10 mg/kg/dose had the least drain output and total blood loss compared to the 
group who received either one or two doses of the drug perioperatively, suggesting that 
serial dosing allows for optimal perioperative efficacy50.  A prospective study by Alvarez 
et al also showed that a cohort of TKA patients receiving IV TEA as a bolus prior to 
tourniquet release supplemented by a 1 mg/hr infusion for 6 hours postoperatively had 
significantly decreased levels of drain and total calculated blood loss.  In this study, the 
quoted number needed to treat to avoid one unit of blood transfused (autologous or 
allogeneic) is 9.2, further highlighting the efficacy of IV TEA in decreasing blood loss 
and rate of transfusion for patients having TKA51.   
Logistical barriers do, however, make timed serial dosing strategies and continuous bolus 
infusion difficult to administer, especially as the arthroplasty patient transitions to the 
postoperative recovery phase.  There are single-bolus regimens that have shown to be 
safe effective and safe.  A large-scale retrospective review of TKA cases performed 
before and after the implementation of a perioperative TEA protocol, consisting of a 
single IV TEA dose of 20 mg/kg prior to tourniquet release, showed significant 
reductions in hemoglobin drop and blood transfusion rates postoperatively46.  The higher 
dose used in this protocol, much like other studies of relevance, did not show any 
clinically significant increase in thromboembolic complications. 
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2.2 Topical Tranexamic Acid in Total Knee Arthroplasty 
There is also Level I evidence to support the use of topical TEA for reduction of blood 
loss after TKA.  A recent clinical trial showed equivalent efficacy of a 1.5 and 3-gram 
topical TEA solution in reducing calculated blood loss by factor of approximately 25% 
compared to placebo39.  In this study, a valuable addition to the clinical trial protocol is 
the biochemical analysis of plasma levels of TEA, measured one hour after 
administration in all treatment groups.  The 1.5-gram topical dose resulted in significantly 
lower systemic load than the group receiving the higher dose, with no differences in the 
desired clinical effect.  In a further attempt to contrast the effect of the different routes of 
administration on postoperative blood loss, Seo and colleagues published results of their 
three-armed prospective cohort study demonstrating modest improvements in hemostasis 
and drain output in the treatment arm receiving IA TEA, when compared to both IV TEA 
and placebo52.  Although the latter group was only administered IV TEA after the 
surgical site was closed, this study provides further evidence in support of IA or topical 
administration of TEA in TKA.  A review of recent studies examining the use of TEA in 
TKA is presented in Table 2.1. 
Table 2.1: Selected Studies Evaluating the Use of Tranexamic Acid in Total Knee 
Arthroplasty. 
Treatment Arms Blood Loss Transfusion Complications 
Good et al (2003)48 
1. IV TEA bolus 10 mg/kg at 
tourniquet release + repeat 10 
mg/kg bolus 3 hours later; n=27. 
2. Placebo; n=24 
TEA < placebo 
(total) 
 
TEA = placebo 
(hidden) 
TEA < placebo TEA = placebo 
Alvarez et al (2008)51 
1. IV TEA 1 gram bolus at 
tourniquet release + 1 mg/kg/hr 
infusion for 6 hours postop; n=46 
2. Placebo; n=49 
TEA < placebo 
TEA < placebo 
(alloRBC) 
 
TEA < placebo 
(autoRBC) 
NR 
Ralley et al (2010)46 
1. IV TEA bolus 20 mg/kg bolus at 
incision; n=150 
2. Placebo; n=145 
TEA < placebo TEA < placebo TEA = placebo 
Wong et al (2010)39 
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Treatment Arms Blood Loss Transfusion Complications 
0. Placebo; n=35 
T1. Topical TEA 1.5 grams at 
closure; n=31 
T2. Topical TEA 3 grams at 
closure; n=33 
T1 < placebo 
 
T2 < placebo 
 
T1 = T2 
TEA = placebo TEA = placebo 
Charoencholvanich and Siriwattanasakul (2011)53 
1.  IV TEA 10 mg/kg pre-
tourniquet inflation + repeat 10 
mg/kg bolus 3 hours postop + 500 
mg TID orally x 5 days postop; 
n=50 
2.  Placebo; n=50 
TEA < placebo TEA < placebo TEA = placebo 
Maniar et al (2012)50 
0. Placebo; n=40 
T1. IV TEA bolus 10 mg/kg at 
tourniquet release; n=41 
T2. IV TEA bolus 10 mg/kg at 
tourniquet release + repeat 10 
mg/kg bolus 3 hours postop; n=42 
T3. IV TEA bolus 10 mg/kg prior 
to tourniquet inflation + repeat 10 
mg/kg bolus at tourniquet release; 
n=42 
T4. IV TEA bolus 10 mg/kg prior 
to tourniquet inflation + repeat 10 
mg/kg bolus at tourniquet release + 
repeat 10 mg/kg bolus 3 hours 
postop; n=41 
LA. Topical TEA 3 grams at 
closure; n=41 
LA < T1 
 
T3 < placebo 
 
T4 < placebo 
 
LA < placebo 
TEA = placebo TEA = placebo 
Seo et al (2012)52 
1. IA TEA 1.5 grams at closure; 
n=50 
2. IV TEA bolus 1.5 grams at 
closure; n=50 
3. Placebo; n=50 
IA < placebo 
 
IV < placebo 
 
IA < IV 
IA < placebo 
 
IV < placebo 
 
IA = IV 
IA = IV 
 
IA = placebo 
 
IV = placebo 
Aguilera et al (2013)49 
1. BSTC Fibrin Glue; n=42 
2. Tissucol; n=41 
3. IV TEA bolus 1 gram x 2, first 
dose prior to tourniquet inflation, 
second dose prior to tourniquet 
release; n=41 
4. Placebo; n=42 
TEA < placebo 
 
TEA < fibrin 
TEA < fibrin 
 
fibrin = placebo 
TEA = fibrin = 
placebo 
Georgiadis et al (2013)54 
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Treatment Arms Blood Loss Transfusion Complications 
1. Topical TEA 2 grams at closure; 
n=50 
2. Placebo; n=51 
TEA < placebo TEA < placebo TEA = placebo 
Konig et al (2013)55 
1. IA TEA 3 grams at closure; 
n=130 
2. Placebo; n=29 
TEA < placebo TEA < placebo NR 
Alshryda et al (TRANX-K; 2013)56 
1. Topical TEA 1 gram at closure; 
n=79 
2. Placebo; n=78 
TEA < placebo TEA < placebo TEA = placebo 
Oremus et al (2014)30 
1. IV TEA bolus 1 gram at incision 
+ repeat 1 gram bolus 3 hours later; 
n=29 
2. Placebo; n=27 
TEA < placebo 
(intraoperative) 
 
TEA < placebo 
(drain loss) 
IV TEA < 
placebo 
(autoRBC) 
 
IV TEA = 
placebo 
(alloRBC) 
TEA = placebo 
*IV: Intravenous TEA.  IA: Intra-Articular TEA.  AutoRBC: Autologous Blood Reinfusion.  
AlloRBC: Allogeneic Blood Transfusion.  “<”: Less than.  “=”: Equal to.  NR: Not Reported. 
 
2.3 Intravenous Tranexamic Acid in Total Hip Arthroplasty 
Like in TKA, IV TEA has been shown to be effective, safe, and relatively easy to 
administer to patients undergoing primary THA.  Appropriate timing of IV TEA 
administration is paramount.  One of the first studies on the subject was a small double-
blinded trial by Benoni, concluding no benefit with regards to blood loss when the drug 
was infused after implantation of the prosthesis57.  A similar placebo-controlled study 
demonstrated that IV TEA administered prior to the start of the procedure showed 
significant benefit for both intra- and postoperative blood loss in the treatment group58.  
Although the sample size in these clinical trials is small, the contrasting results highlight 
the importance of appropriate timing of administration. 
Variation also exists in the published protocols for IV administration of TEA during 
THA.  There does not appear to be strong benefit of either a single-dose or multi-dose 
regimen when the drug is used in hip surgery.  A retrospective review of five separate 
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regimens of IV TEA in THA showed benefit in decreasing drain output when 
administering the drug prior to skin incision with a repeat bolus dose 6 hours later59.  In 
contrast, a study published in 2005 by Johansson demonstrated that a single dose of 15 
mg/kg, given at the start of the procedure, is effective in decreasing calculated blood loss 
and the need for transfusion in the postoperative period60.  Similarly, at our institution, 
we demonstrated a significant benefit with regards to decreased rate of transfusion when 
a single bolus dose of 20 mg/kg given prior to skin incision was used in THA.  In this 
latter study, the postoperative drop in hemoglobin was attenuated in the cohort of patients 
having received IV TEA, in addition to an observed decrease in the rate of postoperative 
allogeneic blood transfusion46. 
 
2.4 Topical Tranexamic Acid in Total Hip Arthroplasty 
Although limited, evidence supporting the use of topical TEA in THA continues to grow.  
Preliminary evidence emanating from a randomized controlled trial by Konig et al 
demonstrates that a protocol of topical TEA administered topically at three intraoperative 
steps during THA (after acetabular preparation, femoral broaching, and at closure of the 
arthrotomy) provides significant reductions in blood loss compared to placebo, with a 
negligible reduction in transfusion rate55.  The European TRANX-H study also provides 
Level I evidence for use of topical TEA in primary THA, noting a significant decrease in 
transfusion rate in the group receiving 1 gram of topical TXA infiltrated into the joint 
prior to arthrotomy closure compared to placebo56.  The evidence for routine use of 
topical TEA, however, lags behind the literature available for topical or intra-articular 
TEA in TKA.  Higher-powered clinical trials are needed to further evaluate the efficacy 
and safety of administering TEA topically in THA.  A review of recent studies examining 
the use of TEA in THA, administered both intravenously and topically, is presented in 
Table 2.2. 
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Table 2.2: Selected Studies Examining the Use of Tranexamic Acid in Total Hip 
Arthroplasty. 
Treatment Arms Blood Loss Transfusion Complications 
Benoni et al (2000)57 
1. IV TEA bolus 10 mg/kg at closure + 
repeat 10 mg/kg bolus 3 hours later; 
n=20 
2. Placebo; n=19 
TEA = placebo TEA = placebo TEA = placebo 
Ekback et al (2000)58 
1. IV TEA bolus 10 mg/kg at incision + 
repeat 10 mg/kg bolus 3 hours later; 
n=20 
2. Placebo; n=20 
TEA < placebo 
(intraoperative) 
 
TEA < placebo 
(postoperative) 
NR TEA = placebo 
Husted et al (2003)61 
1. IV TEA bolus 10 mg/kg bolus at 
incision + 1 mg/kg/hr x 10 hours 
postop; n=20 
2.  Placebo; n=20 
TEA = placebo 
(intra-operative) 
 
TEA < placebo 
(postoperative) 
 
TEA < placebo 
(total) 
TEA < placebo TEA = placebo 
Garneti et al (2004)62 
1. IV TEA bolus 10 mg/kg bolus at 
incision; n=25 
2. Placebo; n=25 
TEA = placebo 
(intraoperative) 
 
TEA = placebo 
(postoperative) 
TEA = placebo TEA = placebo 
Johansson et al (2005)60 
1. IV TEA bolus 15 mg/kg at incision; 
n=47 
2. Placebo; n=53 
TEA < placebo TEA = placebo NR 
Niskanen et al (2005)63 
1. IV TEA bolus 10 mg/kg bolus at 
incision + repeat 10 mg/kg bolus q8h x 
2; n=19 
2.  Placebo; n=20 
TEA < placebo NR TEA = placebo 
Yamasaki et al (2005)64 
1.  IV TEA bolus 1 gram bolus at 
incision; n=21 
2.  Placebo; n=21 
TEA = placebo 
(intra-operative) 
 
TEA < placebo 
(postoperative) 
NR TEA = placebo 
Ralley et al (2010)46 
1.  IV TEA bolus 20 mg/kg bolus at 
incision; n=109 
2.  Placebo; n=89 
TEA < placebo TEA < placebo TEA = placebo 
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Treatment Arms Blood Loss Transfusion Complications 
McConnell et al (2011)65 
1.  IV TEA bolus 10 mg/kg at incision; 
n=22 
2.  Fibrin spray; n=22 
3.  Placebo; n=22 
TEA < placebo 
 
TEA = fibrin 
NR NR 
Imai et al (2012)59 
T0. Placebo; n=22 
T1. IV TEA 1 gram at closure; n=24 
T2. IV TEA bolus 1 gram at closure + 
repeat 1 gram bolus 6 hours later; n=20 
T3. IV TEA bolus 1 gram at incision; 
n=25 
T4. IV TEA bolus 1 gram at incision + 
repeat 1 gram bolus 6 hours later; n=26 
T3 < placebo 
(intraoperative) 
 
T4 < placebo 
(intraoperative) 
 
T3 < placebo 
(postoperative) 
 
T4 < placebo 
(postoperative) 
TEA = placebo NR 
Alshryda et al (TRANX-H; 2013)56  
1. Topical TEA 1 gram at closure; n=80 
2. Placebo; n=81 TEA < placebo TEA < placebo TEA = placebo 
Konig et al (2013)55 
1. Topical TEA 3 grams in divided 
doses; n=91 
2. Placebo; n=40 
TEA < placebo TEA < placebo NR 
Oremus et al (2014)30 
1. IV TEA 1 gram bolus at incision + 
repeat 1 gram bolus 3 hours later; n=20 
2. Placebo; n=22 
TEA = placebo 
(intraoperative) 
 
TEA < placebo 
(postoperative) 
TEA < placebo 
(autoRBC) 
 
TEA = placebo 
(alloRBC) 
TEA = placebo 
*AutoRBC: Autologous Blood Reinfusion.  AlloRBC: Allogeneic Blood Transfusion.  NR : Not 
Reported. 
 
2.5 Thromboembolic Risk of Perioperative Antifibrinolytic 
Therapy 
To date, multiple systemic reviews, meta-analyses and randomized clinical trials, 
including thousands of patients, have failed to demonstrate an increased risk of 
thromboembolic events when TEA is used in primary TKA or THA, as outlined in Table 
2.3.  Based on the results of these studies, the risk remains theoretical.  Perhaps the most 
convincing evidence comes from a systematic review published in 2009, showing no 
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significant difference in rates of reported thromboembolic events in 949 patients 
receiving antifibrinolytic therapy as adjunctive therapy prior to TKA or THA66.  Caution 
must be taken when interpreting these studies; patient selection remains an important step 
when considering the use of tranexamic acid.  Although not always clearly stated, most 
published series in TKA and THA exclude potential subjects with a medical history of 
coagulopathy, cerebrovascular event(s), or any thromboembolic event.  In some studies, 
patients having undergone cardiac stenting, as well as females on long-term estrogen 
replacement therapy have also been excluded from receiving TEA.  Further evidence is 
needed to supporting the administering of TEA in these higher-risk patient populations, 
for any of the documented routes of administration. 
Table 2.3: Systematic Reviews and Meta-Analyses Assessing Antifibrinolytics in 
Lower Extremity Total Joint Arthroplasty. 
Procedure Comparison No. Studies Blood Loss Transfusion Complications 
Ho and Ismail (2003)67 
1° TKA 
1° THA 
1. IV TEA 
2. Placebo 12 TEA < placebo TEA < placebo TEA = placebo 
Cid and Lozano (2005)68 
1° TKA 1. IV TEA 2. Placebo 9 NR TEA < placebo NR 
Gill and Rosenstein (2006)69 
1° TKA 
RevTKA 
1° THA 
RevTHA 
1. IV TEA + 
Apr 
2. IV TEA 
3. Apr 
4. Placebo 
13 
All < placebo 
(intraoperative) 
 
All < placebo 
(total) 
All = placebo All = placebo 
Zufferey et al (2006)70 
1° TKA 
RevTKA 
1° THA 
RevTHA 
Spine 
Tumor 
1. IV AFlytic 
2. Placebo 
23 Apr 
20 TEA 
2 EACA 
NR 
Apr < placebo 
 
TEA < placebo 
 
EACA = 
placebo 
AFlytic = 
placebo 
Kagoma et al (2009)66 
1° TKA 
1° THA 
1. IV AFlytics 
(Apr, TEA and 
EACA) 
2. Placebo 
29 AFlytic < placebo 
AFlytic < 
placebo 
AFlytic = 
placebo 
Sukeik et al (2011)71 
1° THA 
1. IV TEA 
2. Placebo or 
other AFlytic 
11 
TEA < placebo 
(intra-operative) 
 
TEA < placebo TEA = placebo 
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Procedure Comparison No. Studies Blood Loss Transfusion Complications 
TEA < placebo 
(postoperative) 
Gandhi et al (2013)72 
1° TKA 
1° THA 
1. TEA (IV, 
IA or Top) 
2. Placebo 
29 IV 
3 IA 
1 Top 
TEA < placebo TEA < placebo TEA = placebo 
Zhou et al (2013)73 
1° THA 1.  IV TEA 2.  Placebo 19 
TEA < placebo 
(intraoperative) 
 
TEA < placebo 
(postoperative) 
TEA < placebo TEA = placebo 
*EACA:  Epsilon-Aminocaproic Acid.  Apr: Aprotinin.  IV: Intravenous.  IA:  Intra-Articular.  
AFlytic: Antifibrinolytic (includes TEA, EACA, and Apr).  NR: Not Reported.  
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3 TeACH-R Trial Methodology 
 
The purpose of our study is to compare the clinical efficacy of TEA given both 
intravenously prior to skin incision and topically at the time of arthrotomy closure during 
THA.  A single-blinded, parallel group randomized controlled trial (RCT) forms the basis 
of our investigation.  During the Study Initiation, Recruitment and Data Collection Phase, 
the study is colloquially termed the Tranexamic Acid Comparison in Hip Replacement 
(TeACH-R) Trial. 
 
3.1 Clinical Trial Design 
Well-designed randomized controlled trials provide sound Level I evidence for or against 
the use of a particular intervention, in accordance with the Oxford Centre for Evidence-
Based Medicine 2011 Levels of Evidence74.  Our study design uses a parallel group 
design, with one treatment arm receiving intravenous TEA, the other receiving topical 
TEA.   There is no placebo group in this trial; the active comparator is the intravenous 
tranexamic acid group, as this route of administration is considered the standard of care 
for primary THA at London Health Sciences Centre, University Hospital (LHSC-UH). 
3.1.1 Ethics Board Approval 
The Western University Health Science Research Ethics Board (HSREB#104559) and 
the Lawson Health Research Institute Clinical Impact Research Committee (CRIC#R-14-
130) have approved the TeACH-R Trial for use of human participants in clinical 
research.  Documentation of HSREB approval is provided in Appendix B.  The clinical 
trial has also been registered into the public domain on clinicaltrials.gov 
(NCT#02056444). 
3.1.2 Source of Funding 
The TeACH-R Trial is supported by a Resident Research Grant (RRG) valued at $5000 
Canadian Dollars, distributed as part of the Internal Research Fund from the Western 
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University Department of Surgery.  No other sources of external funding were required to 
support the administrative or logistical needs of the study. 
3.1.3 Randomization 
Randomization assures that best efforts are made to equalize treatment groups with 
regards to demographic variables and expected prognosis.  By allocating enrolled study 
participants to separate treatment groups, bias for treatment outcome is minimized.   
Inclusion and exclusion criteria help to define those patients screened for study inclusion 
by identifying factors that are known determinants of outcome.  Minimizing bias related 
to unknown or uncontrollable determinants of outcome is corrected for by allocating to 
treatment groups on a random basis. 
There are a number of ways to randomize effectively.  Computer-generated random 
sequencing programs offer a straightforward and reliable method.  Sealed opaque 
envelope concealment is also effective, and easy to administer.  With the latter technique, 
however, there is the potential for error or investigator-driven allocation if envelopes are 
improperly sealed, or if the result of the allocation is visible through the envelope.  We 
proceeded with sealed-envelope concealment, ensuring that tamper-proof manila 
envelopes were opened in succession. 
In an attempt to keep even numbers between the treatment groups, a block randomization 
protocol was used.  For every 20 participants enrolled into the study, 10 were to be 
randomized to the intravenous TEA group, and 10 to the topical TEA group.  
Randomization to receive either intravenous or topical TEA during primary THA 
occurred prior to the start of the procedure.  As outlined in Section 3.2.3, verbal consent 
was obtained via telephone conversation with the potential participant prior to the 
operative date.  Once verbal consent was confirmed, randomization to one of the two 
treatment arms proceeded. 
3.1.4 Blinding 
Blinding, as it relates to clinical trial research methodology, refers to the awareness of 
treatment group allocation for study participants.   A study is single-blinded if either the 
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participant or investigator is unaware of treatment group allocation.  A double-blinded 
study, on the other hand, implies that both the participant and investigator are blinded.  
The TeACH-R trial is blinded to patients only, as all outcome measures are objective in 
nature.  TeACH-R investigators responsible for consent, randomization and data 
collection do not direct patient care.  Patients may, however, be biased to disclose 
relevant medical information in the postoperative period if left unblinded.  Willingness to 
disclose an adverse event could be influenced by patient perception, should he or she 
know which treatment group they have been allocated to.  For example, a participant may 
feel that there is an increased risk of thrombotic events with the intravenous TEA; the 
threshold to seek investigations for swelling or leg pain might be lower than if the 
participant was not blinded to the treatment received.  The investigators have designed 
the study to decrease this reporting bias; patients can only find out by which route they 
have received the drug after the final outpatient follow-up, at 3 months after total hip 
replacement.  Data was unblinded at a specific time point after recruitment (April 1, 
2014) in order to perform interim statistical analysis.  All outcome measures are objective 
in nature, with no potential of introducing bias into the data collected as part of the 
TeACH-R study protocol.  Only the primary author (R.P.N.) holds access to the data; 
consultant surgeons contributing to study development are not granted access to view, 
edit or input data pertaining to the TeACH-R trial. 
3.2 Recruitment 
The recruitment phase for the TeACH-R trial began in April 2014 and is ongoing. The 
process of approaching and enrolling potential participants is outlined below. 
3.2.1 Eligibility 
The goal of this study is to capture primary total hip arthroplasty (THA) patients who 
would otherwise be receiving IV TEA as the standard of care at our institution.  Inclusion 
criteria are meant to represent the typical patient proceeding to elective THA, and are 
listed in Table 3.1.  Five of seven fellowship-trained arthroplasty surgeons at LHSC-UH 
participated in the study.  Two surgeons abstained from study participation.  One surgeon 
cited an unwillingness to administer any intra-articular agent during arthroplasty, while 
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the other utilizes a direct anterior approach for primary THA in patients with a body mass 
index (BMI) below 40 kg/m2.  Above this level, it was felt by this surgeon that the risk of 
postoperative wound problems was significant enough to warrant a direct lateral 
approach, where the incision line is away from the inguinal crease and abdominal pannus 
(personal correspondence).  As this is not the surgeon’s preferred approach to a primary 
THA, and that the baseline risk of complications in morbidly obese patients is 
significantly different than the population targeted with the proposed intervention75, the 
investigators decided to exclude this surgeon’s patients from TeACH-R study 
participation.  Patients from these two consultants were not screened nor contacted by the 
TeACH-R investigators. 
Table 3.1: TeACH-R Trial Inclusion Criteria. 
1. Primary total hip arthroplasty. 
2. Primary diagnosis of osteoarthritis, rheumatoid arthritis, or avascular necrosis affecting 
the operative hip joint. 
3. Age over 18 years. 
4. Plan for cementless hip implant system. 
5. Plan for modified direct lateral (Hardinge) approach, in the lateral decubitus position. 
6. Medically fit for elective surgery. 
7. Consent obtained for blood product administration. 
8. Ability to read and write in the English language. 
 
If the criteria for TeACH-R study inclusion were met at this stage, the subject was 
considered a potential study participant, but could still be disqualified from study 
participation if he or she met any of the exclusion criteria listed in  
Table 3.2.  Exclusion criteria are focused on THA patients with additional risk factors for 
venous thrombotic events (VTE) as well as those with atypical diagnoses requiring THA.  
Patients at higher risk of VTE require thorough medical review prior to treatment with 
TEA, and do not represent the population targeted with this intervention.  The therapeutic 
safety of TEA has not been thoroughly studied in patients at moderate- and high-risk; 
investigators have expressed concern in administering a clot-stabilizing drug to a high-
risk patient undergoing a moderate- to high-risk procedure. 
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Table 3.2: TeACH-R Trial Exclusion Criteria. 
1. Primary total hip arthroplasty for the treatment of acute hip fracture. 
2. Primary diagnosis of post-traumatic osteoarthritis (including those with or without the 
need for removal of hardware prior to prosthetic implantation), or Charcot arthropathy in 
the operative hip joint. 
3. History of developmental dysplasia of the hip, slipped capital femoral epiphysis or Legg-
Calvé-Perthes disease in the operative joint. 
4. Simultaneous bilateral primary THA. 
5. History of VTE in last 12 Months, for any reason. 
6. Lifelong anticoagulation prescribed or recommended for prior VTE. 
7. Concurrent active malignancy receiving chemo- or radiation therapy, or having received 
said therapy in the past 12 months. 
8. Mechanical cardiac valve requiring lifelong therapeutic anticoagulation. 
9. Drug-eluting cardiac stenting within the previous two years to treat coronary artery 
disease, with ongoing clopidogrel (Plavix) therapy. 
10. Documented coagulopathy, blood dyscrasia, or hematologic condition/malignancy. 
11. Documented diagnosis of hemochromatosis with elevations of hemoglobin above normal 
range (> 170 mg/dL), or requiring recurrent phlebotomy. 
12. Documented allergy to TEA. 
13. Preoperative autologous blood donation. 
14. Inability to attend scheduled follow-up appointments with the treating surgeon. 
15. Participation in a concurrent research study at the time of THA 
 
Atypical presentation of degenerative hip disease as a consequence of disease processes 
such as developmental dysplasia of the hip (DDH), slipped capital femoral epiphysis 
(SCFE) and Legg-Calvé-Perthes disease (LCPD) are relatively rare.  These pathologies 
tend to affect patients decades earlier than the typical sufferer of OA, given the 
manifestation of these conditions in childhood.  Younger patients typically have 
competent hematopoietic and cardiovascular systems, and are typically better able to 
withstand the physiologic stress of major orthopaedic surgery compared to those of 
advanced age.   However, this population may still glean benefit from a reduced risk of 
transfusion, especially in young females of childbearing age.  The risk of development of 
autoantibodies possibly affecting future pregnancies is not insignificant in a young 
female after transfusion of blood products.  However, the surgical procedure is often 
more involved than the standard THA, due to the longstanding nature of hip pathology 
with consequent anatomic abnormalities.  In LCPD and SCFE, altered femoral head 
shape can lead to significant bone loss in and around the acetabulum.  Surgeons 
incorporate structural bone grafts or metallic augments to support the implanted 
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acetabular shell given these bony deficiencies.  Dealing with these bone defects adds time 
and labor to the standard THA.  Hip dysplasia surgery may also require femoral 
shortening osteotomies in severe deformities to bring the hip center back to its anatomic 
position.  These accessory steps within the procedure, not commonly performed in 
elective primary THA, prolong the time of surgery and increase blood loss.  Moreover, 
additional manipulation of the operative extremity can increase the risk of clot formation 
due to repeated endovascular disruption.  From a research methodology perspective, 
these factors are significant confounders, and have the potential to skew the data in an 
unfavorable manner.  Although TEA may be of benefit, patients affected by these disease 
processes are not representative of the typical arthroplasty patient population.  Given the 
lack of evidence supporting the use of TEA in patients with these primary diagnoses, 
patients with DDH, LCPD and SCFE in the operative extremity were excluded from the 
TeACH-R study. 
Adult avascular necrosis (AVN) of the hip represents a different etiological entity than 
those mentioned above.  Subjects with AVN as a primary diagnosis are eligible for study 
inclusion.  AVN often results in irreversible femoral head collapse due to weakening of 
subchondral bone.  Clinical presentation is variable.  Altered joint motion due to the 
misshapen femoral head results in progressive degenerative changes within the hip joint.  
Often, clinical deterioration is rapid compared to OA or inflammatory arthritis, and 
symptomatology dictates the need for THA early in the natural history of this aggressive 
disease.  Femoral or acetabular bone loss is infrequently seen in AVN; therefore the 
surgical procedure is typically similar to a standard cementless primary THA for primary 
OA.  For this reason, TEA can still be of benefit in patients affected by this disorder. 
Subjects with inflammatory arthropathy as a primary diagnosis are eligible for study 
inclusion.  Rheumatoid arthritis (RA) is a common form of inflammatory arthropathy.  
The inflammatory process within the hip joint results in both erosive and degenerative 
changes heralding the need for THA.  The patient with inflammatory arthropathy often 
has concurrent alterations in their hematologic profile, with decreased hematopoietic 
potential.  Commonly, these patients are anemic preoperatively and have pre-formed 
autoantibodies as a result of immunologic dysregulation.  The prevalence of anemia in 
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patients with RA is thought to be anywhere from 30 to 60 percent.  In combination, both 
iron-deficiency anemia from longstanding anti-inflammatory use and anemia of chronic 
disease due to autoimmune attack on hematopoietic cells within the bone marrow 
contribute to the increased prevalence of anemia in RA patients76.  Avoidance of 
transfusion in the rheumatoid population is therefore paramount; procuring an allogeneic 
match is often difficult, costly, time-consuming, and exposure to repeated transfusion 
increases the risk of forming additional allo-antibodies77.  The benefits of administering 
TEA far outweigh the risks for the patient with inflammatory arthropathy needing THA 
for the management of symptomatic hip disease. 
3.2.2 The Preoperative Medical Evaluation 
Once the determination has been made to proceed with surgery to replace the 
degenerative hip joint, all arthroplasty patients at LHSC-UH undergo a thorough medical 
review in the Pre-Admission Clinic (PAC).  This is in addition to the orthopaedic-specific 
medical history taken at the time of initial consultation with the treating surgeon.   At this 
PAC visit, Orthopaedic Nurse Practitioners (ONP) are tasked with performing a thorough 
review of systems, documenting all preoperative medications, and placing day-of-
procedure orders, to be implemented as the patient arrives to the Surgical Preparation 
Unit on the day of the elective procedure.  Specialist Internal Medicine or Anaesthesia 
consultations are completed during the PAC visit, should the need arise based on medical 
conditions identified during the orthopaedic consultation or ONP medical review. 
Timing of the PAC visit is meant to provide up-to-date medical information to all 
involved in the care of the arthroplasty patient.  The planned date of the surgical 
procedure is known, and the PAC appointment is scheduled anywhere from 1 week to 3 
months prior to the surgical date.  This allows for enough time preoperatively to order 
urgent investigations, if necessary, and to advise on medication profile alterations, 
without changing the date of surgery.  Updated blood work, including a complete blood 
count (CBC), is drawn if the planned procedure is more than 3 months from the date of 
the most recent available values.  The CBC includes the hemoglobin (Hgb) and 
hematocrit level (Hct); values nearest to the operative date and time are used as baseline 
for the calculation of perioperative blood loss in this study. 
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The order for TEA is placed electronically at the PAC visit, along with other day-of-
procedure orders.  The ONP is responsible for assessing the need and eligibility for 
intraoperative TEA administration, based on the Medical Directive set by the 
Perioperative Blood Conservation Program (PBCP).  The latter outlines the 
circumstances where TEA can be given safely to patients undergoing both THA and 
TKA (See Appendix D).  The majority of arthroplasty patients fall into one of two 
categories: (1) no concern exists with regards to TEA administration, or (2) an absolute 
contraindication exists within the patient’s medical profile.  In the first scenario, the ONP 
places the order after the PAC encounter is completed.  In the latter scenario, no TEA 
order is placed on the chart. 
If any element of the patient medical history raises concern with regards to the safety of 
administration of TEA, further review by the PBCP is indicated.  The PBCP is composed 
of a number of specialist physicians, including hematologists, surgeons and 
anaesthesiologists, whose main responsibility is the creation of policies to optimize the 
use of cost-effective and safe blood conservation protocols in the perioperative setting.  
On a case-by-case basis, three individuals work in unison to determine eligibility for TEA 
administration: a supervising physician with subspecialty interest in perioperative 
medicine and blood conservation (the Director), working in direct consultation with two 
PBCP nurse practitioners.  Final determination of perioperative TEA administration in 
equivocal cases comes after the PCBP Director performs a thorough medical review and 
risk-benefit analysis.  This process is unaffected by the TeACH-R protocol. 
3.2.3 Informed Consent 
Informed consent for study participation was obtained pre-operatively for all study 
participants.  The process of informed consent was undertaken as per Good Clinical 
Practice (GCP) standards.  Possible study participants were identified by thorough review 
of surgical lists.  A chart review was undertaken for subjects meeting TeACH-R study 
inclusion criteria.  If no exclusion criteria were identified based on the available 
information contained within the subject’s chart, contact was made prior to the day of the 
procedure, either by telephone or at the PAC visit.  Usually, the study participant had 
completed the PAC appointment with day-of-procedure orders visible on the electronic 
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chart before being contacted by a member of the research team.  This process enabled the 
research team to select study participants whom had already been ordered TEA by either 
the ONP or PBCP. 
Verbal consent was obtained at the time of initial patient contact. Written informed 
consent was then obtained on the morning of surgery, where the study objectives and 
protocol were reviewed, and all questions answered.  A copy of the written consent form 
is provided in Appendix C.  Subjects were deemed to be enrolled in the study only after 
written informed consent was signed and dated; the option to decline participation was 
allowed up until this point.  Should a patient enrolled in the topical TEA treatment arm 
decline participation preoperatively, he or she would still receive the standard of care, 
intravenous TEA, prior to skin incision. Consent can be retracted postoperatively, at the 
participant’s request.  Although he or she would have received treatment based on 
randomized allocation to a treatment arm, participant data is not to be included as part of 
the final analysis.  
Signed original consent forms are kept in a locked room in a secure facility at University 
Hospital.  The Western HSREB requires that these consent forms be maintained for ten 
years after completion of the enrollment phase of the TeACH-R study.  A copy of the 
signed consent form was provided to all study participants at the time of formal study 
enrollment. 
 
3.3 Treatment Arms 
3.3.1 Intravenous Tranexamic Acid 
At LHSC-UH, intravenous TEA is given to all patients undergoing primary THA so long 
as a particular patient does not have a contraindication to TEA administration.  This is 
considered standard of care for both TKA and THA.  Preparation of the medication is 
done the night prior to the procedure, by the Inpatient Pharmacist, with a weight-based 
dose of 20 mg/kg TEA mixed in a 50 mL bag of 0.9% sodium chloride.  This is 
refrigerated overnight at 4° Celsius, sent to the Surgical Preparation Unit on the morning 
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of surgery and appended to the patient’s chart (see Figure 3.1).  The preparation travels 
with the patient to the Operating Room (OR), where it is administered 10 minutes prior to 
skin incision for THA via intravenous injection by the anaesthesiologist assigned to the 
OR on that particular day.  For the purposes of this study, intravenous TEA is considered 
active five minutes after completion of the infusion, as the drug has had enough time to 
redistribute into the joint space. 
 
Figure 3.1: Intravenous Tranexamic Acid Preparation. 
 
As discussed in Chapter 2, both single-dose and serial dosing TEA regimens are 
prevalent in the literature.  Logistical barriers related to patient transport, equipment, and 
nursing exist in the perioperative setting that can impair the implementation of a reliable 
multi-dose or TEA-infusion protocol.  We elected to use a single-dose regimen of 20 
mg/kg given immediately prior to skin incision.  This protocol is the standard of care 
currently in use at LHSC-UH for THA.  This has proven effective at our institution in 
reducing blood loss without a concomitant rise in thromboembolic events post-THA46. 
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3.3.2 Topical Tranexamic Acid 
Topical TEA is prepared in a similar fashion to the intra-articular preparation used in 
TKA.  Like the intravenous TEA group, the Inpatient Pharmacist prepares the solution 
the night prior to the procedure.  However, in the topical TEA group, a standardized 
solution of 1.5 grams in a 50 mL solution of 0.9% sodium chloride is prepared.  The 
solution is contained within a sterile syringe sent to the Surgical Preparation Area, and 
subsequently to the OR with the study participant (see Figure 3.2).  For subjects allocated 
to this treatment arm, no intravenous TEA is administered prior to skin incision. Instead, 
the solution is applied to the joint area intraoperatively by the treating surgeon.  This 
takes place with the final implants in situ after final reduction of the prosthetic 
components.  The entirety of the 50 mL TEA solution is applied to the joint prior to 
closure of the gluteus minimus and capsular tissue layers.  The solution bathes the hip 
joint and surrounding tissues for a minimum of 5 minutes.  Closure of the arthrotomy can 
continue during this waiting period, provided the solution is not suctioned away. 
 
Figure 3.2: Topical Tranexamic Acid Preparation. 
 
Timing and dosage are important considerations when TEA is administered via the 
topical route.  Optimal timing of administration must parallel the timing of expected 
increases in blood loss.  In THA, the majority of intra-articular blood loss emanates from 
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cancellous bone at the sites of the femoral neck osteotomy and acetabular reaming.  This 
continues postoperatively until local hemostasis is achieved.  We elected to target 
reductions in perioperative blood loss by infiltrating TEA after the intramedullary 
femoral canal has been filled with the stem of the press-fit femoral implant, and the 
acetabular cup sealed with the press-fit shell.  In this fashion, we target sites of continued 
postoperative bleeding not amenable to electrocautery or ligation.  This corresponds 
primarily to the exposed cancellous bone of the proximal femoral shaft, where TEA can 
act to inhibit the local fibrinolytic process postoperatively.  In a recent study, Konig et al 
infiltrated 3 grams of TEA at three separate time points intraoperatively with good 
clinical outcomes with regards to blood loss55.  In principle, this represents a useful 
strategy to maintain intra-articular does of TEA from the start through to the end of the 
operation.  However, the investigators and arthroplasty surgeons felt the additional doses 
would result in intraoperative time delays due to the mandatory waiting period after TEA 
infiltration, potentially increasing the risk of infection.  A single-dose regimen targeting 
the predominant source of blood loss was adopted for the purposes of this study. 
Dosage of topical TEA was also an important consideration in the development of this 
study.  There is little available evidence to guide the optimal dosing protocol for topical 
TEA administration in THA.  However, to reiterate the aforementioned study by Wong et 
al, a 1.5 gram topical dose of TEA was shown to be effective in reducing blood loss when 
administered during TKA, with a clinically favorable systemic absorption profile39.  
Using this data, we chose to proceed with the identical dosing strategy for TeACH-R 
study participants undergoing primary THA.  As surgical drains are no longer standard 
practice amongst the arthroplasty surgeons at our institution for THA, serial dosing of 
topical or intra-articular agents is not possible in the postoperative period. 
 
3.4 Surgical Considerations 
3.4.1 Operative Technique 
A thorough description of key principles and approaches for THA is available in Section 
1.2.1.1.  The standard operative procedure for a primary cementless THA has been 
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defined for the purposes of this study. The modified direct lateral (Hardinge) approach, 
using a surgical incision based over the greater trochanter, was used for all study subjects.  
The gluteus minimus and capsular tissue layers were incised as one layer. The capsule 
was not excised following the arthrotomy.  No restrictions were defined regarding the 
sequence of femoral and acetabular preparation, trialing of expected components, or 
prosthetic implantation.  No surgical drains were placed intraoperatively.  All patients 
received the standard weight-based dose of intravenous antibiotics within 30 minutes of 
skin incision.  Typically, cefazolin is the antibiotic of choice.  In cases of severe allergy 
or colonization with methicillin-resistant Staphylococcus aureus (MRSA), vancomycin 
and/or clindamycin are either substituted or added to the preoperative regimen.  To the 
best of the author’s knowledge, there are no known drug interactions between TEA and 
any of these intravenous antibiotics. 
3.4.2 Prosthetic Components 
When it comes to primary hip prostheses, a variety of implants are used at LHSC-UH.  
As per the TeACH-R protocol, choice of final prosthesis and bearing surface is at the 
discretion of the treating surgeon, as long as cementless fixation is used on for both the 
femoral stem and acetabular shell.  If the latter criterion is not met, the patient is excluded 
from the study.  This situation arises most commonly when there is concern of 
diminished bone density, identified intraoperatively, where cemented implants are 
thought to provide improved stability in the setting of poor osteo-integrative potential.  
The use of adjuvant screw placement through the acetabular component was also left to 
the discretion of the treating surgeon.  Participants requiring acetabular screw placement 
as an added measure of stability were not excluded from the final analysis.  Because 
placement of acetabular screws tends to increase operative time and increases the risk of 
bleeding, screw fixation was noted in the final analysis as a demographic variable. 
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3.5 Postoperative Care of the Arthroplasty Patient 
3.5.1 Inpatient Care After Elective Primary Total Hip Arthroplasty 
All patients undergoing total hip arthroplasty follow a standard postoperative pathway.  
The patient is transferred from the OR to the Post-Anaesthetic Care Unit (PACU) for 
close monitoring after completion of the period of anaesthesia.  While in the PACU, the 
treating anaesthesiologist manages multi-modal analgesia protocols as well as any acute 
medical issues.  A plain film radiograph of the pelvis is taken in the PACU shortly after 
arrival in order to assess the position of the implanted components and to rule out 
prosthetic dislocation or unidentified intraoperative fracture.  Occasionally, a CBC is 
drawn in the PACU in cases in which there has been an unusual amount of bleeding intra-
operatively. 
Once the patient is deemed medically stable, he or she is transferred to the orthopaedic 
floor for continued rehabilitation and convalescence.  On the inpatient orthopaedic floor, 
the focus of treatment is on early mobilization in order to reduce the incidence of 
postoperative complications. The surgical team rounds on each arthroplasty patient a 
minimum of once per day, monitoring for complications and tracking progress with 
mobilization.  Daily blood work is routinely drawn the first two mornings after the day of 
surgery.  Standard postoperative blood work consists of a basic hematology, coagulation 
and chemistry panel: CBC, electrolytes (sodium, chloride, potassium, bicarbonate and 
random glucose), blood urea nitrogen (BUN), creatinine (Cr), International Normalized 
Ratio (INR) and partial thromboplastin time (PTT).  Supplementary investigations are 
dependent on clinical suspicion of postoperative pathology, or for monitoring of known 
medical conditions, drug levels, or therapeutic targets.  This study does not alter the usual 
sequence of postoperative investigations.  There is no additional screening or testing 
mandated by the TeACH-R study protocol. 
Throughout the inpatient stay, there is a gradual increase in activity level, with the 
treating surgeon ultimately dictating weight-bearing restrictions based on personal 
preference and intraoperative findings.  Implementation of hip precautions after surgery 
is standardized as per the pathway for THA postoperative care at LHSC-UH.  Patients are 
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advised against hip flexion past 90° and excessive internal or external rotation of the 
thigh in order to prevent prosthetic dislocation.  Given these restrictions, a gait aid is 
usually required for the first 6 weeks postoperatively, which is started in hospital on 
postoperative day 1.  Physio- and occupational therapists see arthroplasty patients in 
hospital and provide daily education and assistance, enabling progression of mobility in 
preparation for a safe discharge from hospital.  Readiness for discharge is a multi-faceted 
process with influence from various members of the interdisciplinary care team, where 
significant emphasis is placed on the patient’s perception of ability to cope at home, 
support systems available to help in recovery, and general medical condition.  Typically, 
patients are ready for discharge on postoperative day two or three following primary 
lower extremity arthroplasty.  The usual discharge prescription consists of pain 
medication(s) and a thromboprophylactic agent to be taken on a routine basis once at 
their discharge destination. 
3.5.2 Thromboembolic Prophylaxis after Primary Total Hip 
Arthroplasty 
Major orthopaedic surgery, which includes THA, is a known risk factor for the formation 
of lower extremity clot.  A deep vein thrombus (DVT), or blood clot, forms due to a 
combination of factors related to Virchow’s triad of vascular thrombosis: endothelial 
injury, hypercoagulability and vascular stasis78.  First, endovascular damage results from 
manipulation of the operative leg.  Second, the release of procoagulant factors during 
bone preparation results in a hypercoagulable state that can persist in the postoperative 
period79, 80. Third, relative immobility during the convalescence phase promotes clot 
propagation due to venous stasis.  If a clot increases to the point of impeding proper 
venous outflow in the affected limb, leg pain and diffuse unilateral swelling ensue, 
usually in the operative extremity.   
Doppler ultrasonography of the lower extremity leg veins is the most commonly used 
method of providing a definitive diagnosis, showing poor compressibility of veins having 
a DVT.  Pulmonary emboli (PE), on the other hand, are embolic phenomena.  A clot in 
the operative (or non-operative) extremity dislodges from its endovascular source and 
subsequently travels through the inferior vena cava, through the right atrium and ventricle 
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past the tricuspid and pulmonic valves, to eventually lodge in the smaller arteries of the 
lung.  The latter can have a variable presentation in the postoperative period. Chest pains, 
shortness of breath, supplemental oxygen dependence, and/or unremitting tachycardia (in 
the absence of any other clinical explanation) are clinical scenarios that can herald the 
onset of thrombus migration to the lungs.  Suspicion for thromboembolic events must be 
high after primary or revision THA because there is a risk of mortality associated with an 
unrecognized embolism.  Diagnosis is confirmed with either a ventilation-perfusion scan 
or computerized tomography of the thorax with concomitant pulmonary arterial and 
venous angiography.  Generally, a low threshold exists for investigating a potential clot. 
Although many promote screening for a lower extremity thrombus after arthroplasty, 
high clinical vigilance and early investigation remains the standard of care in this patient 
population.  Not all clots are symptomatic, nor do all clots require full anticoagulant 
therapy.  The rate of symptomatic or fatal emboli remains unaffected by the presence of a 
radiographic DVT screening protocol, hence it is not recommended by the American 
College of Chest Physicians in their most recent guideline statement17.  Moreover, there 
is currently no evidence to support an increased risk of thromboembolism in patients 
receiving TEA during TKA or THA66, 72.  In keeping with the standard of care at LHSC, 
routine radiographic screening with duplex ultrasonography is not part of the TeACH-R 
trial protocol. 
Postoperative thromboprophylaxis remains part of the postoperative care pathway after 
primary total hip arthroplasty at LHSC-UH.  Many agents, including unfractionated 
heparin (UFH), low-molecular-weight heparins (LMWH), vitamin K antagonists, factor 
Xa inhibitors (FXaI) and direct thrombin inhibitors (DTI) are effective in decreasing 
thromboembolic risk using prophylactic dosing regimens17.  The TeACH-R study 
protocol does not discern which thromboprophylactic agent is used, so long as the study 
subject is on a prophylactic dose postoperatively.  Prior to TeACH-R study initiation, the 
group of arthroplasty surgeons at LHSC completed a thorough review of the current 
evidence on thromboembolic prophylaxis after primary total hip arthroplasty.  The group 
of surgeons using the modified Hardinge approach for THA universally adopted oral 
rivaroxaban 10 mg daily, given in the morning starting postoperative day 1 and 
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continuing for 30 days postoperatively.  Rivaroxaban is a Factor Xa inhibitor growing in 
popularity as a result of well-documented clinical efficacy as a thromboprophylactic 
agent, with the ease of once-daily oral administration20.  The agreed-upon regimen was 
deemed to be safe, effective, and better tolerated by patients compared to subcutaneous 
LMWH, which had been the predominant agent used in the past. 
The thromboprophylaxis regimen at LHSC-UH uses chemical thromboprophylaxis alone, 
without the addition of external compression devices.  Adding intermittent compression 
devices, foot pumps and/or compression stockings is not the standard of practice, as these 
are deemed to be a constant source of patient discomfort, and are a significant 
impediment to mobility during the in-hospital stay.  The benefits of early mobilization 
free of any lower extremity device outweigh the benefit of these external devices.  
Implantable inferior vena cava filters are not used for prophylaxis due to the invasive 
nature of the procedure and marginal clinical benefit. 
Data pertaining to which thromboprophylaxic agent a TeACH-R participant received at 
time of discharge is recorded as part of the study.  Of note, a separate clinical trial 
comparing two DVT prophylaxis protocols combining rivaroxaban and acetylsalicylic 
acid after elective primary THA (the EPCAT-II Study) was underway at LHSC-UH at the 
same time as the TeACH-R Trial.  Because of the possible influence of this latter study 
on rates of DVT and PE, any patient enrolled in EPCAT-II was excluded from TeACH-R 
study participation. 
3.5.3 Transfusion Protocol 
As discussed in Section 1.4.2, strong evidence supports limiting transfusion of packed red 
blood cells (pRBC) in the acute care setting in order to decrease morbidity and mortality.  
Although there are no studies specific to THA, there is definitive evidence stemming 
from two prospective randomized controlled trials, one in critically ill patients patients22, 
and the other in patients having received hip fracture surgery27.  As a result, a restrictive 
transfusion protocol is the standard of care for the arthroplasty service at LHSC-UH.  
TeACH-R study investigators responsible for data collection and analysis, although not 
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directly involved in the postoperative treatment of a study subject, support this 
transfusion strategy, as outlined in Figure 3.3. 
 
Figure 3.3: Restrictive Transfusion Algorithm for Postoperative Anemia in 
Arthroplasty Patients at London Health Sciences Center, University Hospital. 
 
Violations of the restrictive transfusion strategy were recorded.  If a transfusion of 
pRBCs was initiated, all clinical notes from the inpatient stay were reviewed in an 
attempt to find a documented reason for transfusion.  The number of units administered 
was recorded as per the TeACH-R trial protocol. 
Preoperative autologous blood donation (PAD) and postoperative reinfusion (PRI) of 
drained blood after arthroplasty, although not used at LHSC-UH, is still commonplace in 
certain centers.  Issues in incorporation of these modalities as perioperative blood 
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conservation adjuncts are discussed in Section 1.4.3.  Subjects are excluded from the 
TeACH-R trial if these modalities are used in the perioperative period. 
3.5.4 Outpatient Follow-Up 
At LHSC-UH, patients undergoing THA have scheduled follow-up with the treating 
surgeon at the 6-week, 3-month and 1-year mark.  Depending on surgeon preference, a 
patient may also be seen at the 2-week mark for a wound check.  At time of discharge 
from hospital, the first two clinic appointments are coordinated with the surgeon’s office.  
Patients are given strict instruction to contact a member of the surgical team should there 
be any concern related to their surgery in the early postoperative period.  During business 
hours, patients can contact the surgeon’s office directly; after discussion with a member 
of the surgical team, the decision is made to either see the patient in clinic or if urgent, to 
proceed to the Emergency Department at University Hospital for further evaluation.   
Outside of usual business hours, patients have direct telephone access to the on-call 
orthopaedic resident at University Hospital.  This has traditionally been a well-developed 
process for identifying, treating and documenting complications locally. 
TeACH-R study participants are followed for 3 months after surgery.  Contact is made 
with the patient at 2 weeks, 6 weeks and 3 months postoperatively, usually in person at 
the time of outpatient follow-up, where a member of the research team assesses for the 
presence of any postoperative complications.  If in-person contact is not possible, 
completion of the questionnaire is via telephone correspondence by a member of the 
research team.  All clinical notes are reviewed, also with the goal of identifying any 
complications related to the new intervention that are not disclosed by the subject.  The 
TeACH-R study protocol does not mandate any repeat blood work or additional 
investigations at outpatient clinic follow-up appointments.  Loss to follow-up is noted in 
the final analysis. 
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3.6 Data Collection 
Data collection began once the patient has been formally enrolled into the study, has been 
randomized to one of the two treatment arms, and continues his or her postoperative 
course up to the three-month follow-up appointment with the treating surgeon.  All data 
is collected prospectively.  At LHSC-UH most of the available data is contained on the 
patient’s electronic chart (PowerChart, Cerner Corporation, Kansas City, MO), although 
at times reference to the participant’s paper chart is required for further information.  
Data collected is devoid of identifiable patient information, with representative study 
identification numbers assigned to all TeACH-R trial participants.  All collected data is 
contained within study binders stored in a secure location in a locked office, accessible 
only to TeACH-R trial investigators.  A password-protected Microsoft Office Excel 
spreadsheet (Microsoft Corporation, Redmond, WA) also contains de-identified 
participant data for analysis.  This is stored on a secure server (the P: drive) within the 
LHSC computer system, accessible only via secure user login.  In this fashion, 
confidentiality of patient information is ensured throughout the data collection phase.  
The author (R.P.N.) collected all data relevant to the TeACH-R Trial. 
3.6.1 Demographics 
The purpose of collecting demographic data in a prospective randomized controlled trial 
is to ensure that both treatment groups are similar at baseline after randomization.  With 
an appropriate sample size and similar profiles, potential between-group differences in 
the dependent variable(s) are related to the variable controlled by the study itself 
(independent variable); in this study, this would be administration of either intravenous or 
topical TEA.  All demographic variables collected as part of the TeACH-R study are 
listed in Table 3.3.  In addition to basic demographic variables, a number of variables 
pertaining to the surgical procedure and comorbidities were also collected. 
Table 3.3: TeACH-R Demographic Variables. 
Patient-Specific Demographic Data 
 Age (at Time of Surgery) 
 Gender 
 Height (cm) 
 Weight (kg) 
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 Body Mass Index (BMI; kg/m2) 
 Body Surface Area (BSA; m2) 
 Primary Diagnosis (OA, RA, AVN) 
 Preoperative Anemia (Hgb<120 in females, Hgb<130 in males) 
Medical Comorbidities (Charlson Age-Comorbidity Index) 
 Previous Myocardial Infarction 
 Congestive Heart Failure 
 Peripheral Vascular Disease 
 Cerebrovascular Disease (Stroke, Transient Ischemia Attack) 
 Dementia 
 Chronic Obstructive Pulmonary Disease  
 Connective Tissue Disease 
 Peptic Ulcer Disease 
 Diabetes Mellitus (with and without End-Organ Damage) 
 Moderate to Severe Chronic Kidney Disease 
 Hemiplegia 
 Leukemia 
 Malignant Lymphoma 
 Solid Tumour 
 Liver Disease (Mild, Moderate or Severe) 
 Acquired Immunodeficiency Syndrome (AIDS) 
Intraoperative Variables 
 Duration of Procedure 
 Type of Anaesthesia (General or Regional with Sedation) 
 American Society of Anaesthesiologists (ASA) Physical Status Score 
 Acetabular Screw Placement 
3.6.1.1 Combined Charlson Age-Comorbidity Index 
The presence of medical comorbidities is known to alter the risk of postoperative 
complications after THA.  Therefore, assessing the aggregate baseline risk level for each 
treatment group is essential.  As de Groot stated in his 2003 article, “comorbidity can 
either act as a confounder, threatening the internal validity, or as an effect modifier, 
threatening the internal and external validity of the study.”81 The difficulty in assessing 
preoperative risk based on comorbidities lies in filtering through the variety of medical 
diagnoses of relevance, as well as the numerous methods at our disposal to assess 
preoperative risk. 
The Charlson Comorbidity Index, initially described in 1987, is a weighted scale 
inclusive of 19 disease processes, listed in Table 3.3, that has proven to be a useful tool in 
prognosticating outcomes82.  It is also user-friendly, comprehensive, and most 
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importantly, predictive.  The structure of the index allows straightforward assessment of 
risk factors for perioperative complications, in addition to prognosticating long-term 
morbidity and mortality.  It is validated for use in arthroplasty, as it has shown excellent 
validity for mortality, disability, hospital readmission and length of stay81.  When a 
combined age-comorbidity score is used, the impact of increasing comorbidity is easy to 
understand, as per Gold in his 1994 article: “the estimated relative risk of death from an 
increase of one in the comorbidity score proved approximately equal to that from an 
additional decade of age.”83 After a thorough review of the available methods, the 
TeACH-R study investigators felt the combined age-comorbidity score would provide the 
more reliable measure of assessing known preoperative comorbidities for the purpose of 
baseline comparison between both of the treatment arms.  
3.6.1.2 Intraoperative Variables 
When designing a procedure-related RCT, analysis of intraoperative variables is also 
critical, as there can be subtle differences in process for two patients receiving the same 
operation.  Intraoperative proceedings, and how they compare to the standard operating 
procedure, are difficult to assess given the significant heterogeneity in patient anatomy, 
physiology and surgeon preference.  Thankfully, there is available data contained within 
the Intraoperative Record, Anaesthetic Record and Operative Report that allows for some 
standardization between both treatment arms. 
For every patient proceeding to the OR, the attending anaesthesiologist, a specialist in 
perioperative medicine, places significant importance on a through review of medical 
conditions prior to induction of anaesthesia.  The American Society of Anaesthesiologists  
(ASA) Physical Status Score is still commonly used as a standard measure of operative 
risk, despite concerns surrounding scientific precision and limited inter-observer 
reliability84.  The classification system is presented in Table 3.4.  The attending 
anaesthesiologist states and records the ASA Score at the beginning of every case, as part 
of the World Health Organization-mandated surgical debriefing.  This is also recorded as 
per the TeACH-R Trial protocol.  Although less robust than the Charlson Age-
Comorbidity Index, it provides an added measure of assessing preoperative risk based on 
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comorbidity and is helpful in assessing for any baseline between-group differences, in the 
eyes of the anesthesiologist. 
 
Table 3.4: ASA Physical Status Classification System. 
Class 1 A normally healthy patient. 
Class 2 A patient with mild systemic disease. 
Class 3 A patient with severe systemic disease. 
Class 4 A patient with severe systemic disease that is a constant threat to life. 
Class 5 A moribund patient who is not expected to survive without the 
operation. 
Class 6 A declared brain-dead patient whose organs are being removed for 
donor purposes. 
 
The type of anaesthesia is also collected as part of the TeACH-R data set.   Although 
beyond the scope of this study, the influence of the type of anaesthesia, and its resultant 
effect on surgical outcome after TKA or THA, continues to be debated amongst 
anesthesiologists worldwide given a lack of recent high-powered clinical trials.  Meta-
analysis data does, however, suggest that regional anaesthesia decreases operating time 
and the risk of postoperative thromboembolism when compared to general anaesthesia in 
THA85.  There is also a significant effect on surgical blood loss, with decreased 
transfusion requirements reported for THAs done under spinal anaesthesia86.  In general, 
the TeACH-R protocol places few restrictions on the intraoperative process.  No patient 
was included or excluded from the study based on whether they received general or 
regional anaesthesia, but this data was recorded for every study participant. 
From the surgical standpoint, increased surgical time leads to increased blood loss if a 
constant rate of loss is maintained for the duration of the procedure.  The precise start and 
end time of the procedure was also collected from the Intraoperative Record as part of the 
TeACH-R study protocol.  The need for acetabular screw fixation, sometimes required to 
add stability to the acetabular implant after reaming in poor-quality bone, is not expected 
to add significantly to perioperative blood loss as the screws are sealed within the 
implanted shell and threaded into the cortico-cancellous bone of the pelvis.  These are 
placed at final implantation of the acetabular component.  However, the risk of arterial or 
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venous injury potentially leading to hemorrhage and blood loss increases with faulty 
screw placement in an at-risk zone.  The addition of this intraoperative step also increases 
operative time, although generally by a small amount.  For these reasons, both variables 
were also recorded as baseline measures and potential statistical confounders.   
3.6.2 Primary Outcome Measures 
The benefit of introducing TEA into the usual blood conservation for a patient 
undergoing primary THA is to further decrease blood loss.  The predominant risk of 
administering a clot-stabilizing agent during THA is the potential for increased rates of 
thromboembolic complications in the postoperative period.  The primary and secondary 
outcomes measured by the TeACH-R trial attempt to encompass these risks and benefits 
by the most reliable means possible. 
3.6.2.1 Change in Hemoglobin Levels (Delta-Hemoglobin) 
The delta-hemoglobin (ΔHgb), defined for the purposes of the TeACH-R trial as the 
difference between the Hgb value nearest the date of surgery and the lowest measured 
postoperative Hgb, represents a main driver of clinical decision-making with regards to 
the need for transfusion for the control of postoperative blood loss.  It represents one of 
two primary outcomes measures of the TeACH-R trial.  Clinically, should clinical 
concern of acute hemorrhage exists, the first investigation ordered is often a CBC for the 
purposes of determining a Hgb level.  The preoperative Hgb level, a prerequisite for any 
patient undergoing a major surgical intervention where a significant amount of blood loss 
is expected, is also an intuitive marker of underlying red blood cell mass.  Decreases in 
postoperative Hgb level represent loss by one of two mechanisms: (1) external loss 
(hemorrhage) or (2) intrinsic red cell degradation (hemolysis).  In the immediate 
postoperative setting, interpretation of Hgb levels is straightforward, requiring little 
calculation or analysis as loss of red cell mass is predictably due to continued 
extravasation of intravascular volume outside the vascular tree.  Given the period of 120 
days needed for a reticulocyte to mature into a functioning red blood cell, anemia due to 
lack of production of red blood cells is limited to chronic, rather than acute etiologies of 
blood loss. 
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Blood analysis for Hgb levels can be performed rapidly, enabling point-of-care decision-
making in times of need.  The classic clinical presentation of blood loss after THA is 
more gradual in onset, and the treatment consists of transfusion of pRBC as per the 
protocol outlined in Figure 3.3.  Typically, a low Hgb level is discovered incidentally as 
part of the routine postoperative blood work. As explained in Section 3.5.1, postoperative 
blood work is available for the patient’s in-hospital stay, which is used to calculate the 
ΔHgb in the TeACH-R trial.  Unless there is concern for early postoperative infection, no 
further blood work is indicated once discharged from hospital. 
The clinical utility of the Hgb level as a transfusion trigger is well documented.  
However, assessing surgical blood loss based on either isolated Hgb values, or the change 
in Hgb lacks precision.  Commonly used as a surrogate marker of blood loss, it is 
important to note the various factors contribute to one isolated Hgb value drawn in the 
perioperative setting.  One cannot accurately calculate the amount of blood lost using 
Hgb values alone, for a number of reasons.  A falsely elevated Hgb level may result if 
bloodwork is drawn while there is continued bleeding.  Dilution by crystalloid or colloid 
intravascular fluid administration can also alter the apparent red cell mass due to intra- 
and extravascular fluid shifts.  Intraoperative irrigation and suctioning can also alter the 
systemic fluid balance, resulting in potential hemodilution.  Specific to research 
methodology, however, there is great value in interpreting this measure as a scale when 
used as a comparator between groups, assuming that contribution of the other factors to 
Hgb levels remains constant amongst all participants.  In this way, a significant 
difference in the ΔHgb can still indicate a difference in blood loss between groups.  For 
this reason, the determination of ΔHgb in the perioperative setting remains an invaluable 
aid in the assessment of blood loss, which explains its use as a primary outcome in this 
prospective randomized controlled trial. 
3.6.2.2 Calculated Red Blood Cell Loss 
Determining the amount of surgical blood loss is a difficult endeavor, as the value that is 
truly of interest is actually the volume of red blood cells lost during and after the 
procedure.  Red blood cells are the transporters of oxygen within the systemic circulation; 
it is the global increase in oxygen-carrying capacity that transfusion of red blood cell 
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aims to improve.  Given that fluid status changes during and after surgery are dependent 
on the concentration of intra- and extracellular proteins, this can be challenging to predict 
and manage, let alone calculate accurately.  There are a number of ways investigators 
have attempted to quantify perioperative blood loss in the referenced studies mentioned 
in previous chapters.  Some have tried weighing intraoperative sponges, in combination 
with measuring the volume of intraoperative suctioning.  Although commonly referenced 
as an acceptable measure of blood loss, the influence of fluid evaporation and the 
dilutional effect of intraoperative irrigation make this an imprecise measure of 
intraoperative red cell mass lost.  In a similar light, drain output, with and without 
measurement of Hgb values within drain fluid, has been used to measure postoperative 
blood loss.  These are imprecise measures as drain fluid emanating from the surgical 
wound is not the same whole blood lost as a result of surgical trauma.  Inflammatory 
proteins and extracellular fluid infiltration into the surgical wound during the 
postoperative period can significantly influence the actual composition of the drained 
fluid.  In addition to these biological factors, it is not possible to measure postoperative 
drained fluid if no drain is placed intra-operatively, as is common practice at LHSC-UH. 
Pioneering work by Nadler and Gross87, 88, and further work by Blecher89, 90, allow 
researchers and to calculate the volume of red cell loss based on a comparison of 
estimated blood volume (EBV) pre- and postoperatively.  This is based predominantly on 
hematocrit (Hct), defined as the percentage of whole blood that consists of pRBCs.  
Clinically, this is represented as a fraction of 1; for example, a Hct of 0.50 implies that 
50% of whole blood is composed of red blood cells.  Hematocrit takes into account 
dilution and protein composition, enabling calculation of red blood cell mass by 
multiplying the Hct with the EBV.  The formula used for calculation of blood loss can be 
seen in Figure 3.4. 
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Figure 3.4: Calculation of Perioperative Blood Loss.  All blood loss referenced in the 
TeACH-R trial is based on whole blood, assuming Hct of 35 percent.  Initial RBC 
calculated using the Hct and EBV from the preoperative blood draw closest to the date of 
surgery.  Final RBC calculated using the lowest measured postoperative Hct.  EBV is 
based on the most recent height and weight available on the patient’s medical chart.  
(Adapted from Rosencher, N et al. Transfusion 2003; 43(4): 459-69) 
 
Calculation of perioperative blood loss was performed for all patients enrolled in the 
study.  As part of the PAC visit, all study participants had a recent height and weight 
available on the chart, enabling calculation of body surface area (BSA; in m2).  As part of 
the calculation in Figure 3.4, different formulas were used for both men and women, as 
per the formula for predicted blood volume in humans derived by Nadler et al88.  The Hct 
value drawn closest to the operative date was used to calculate the initial RBC.  The final 
RBC calculation used the lowest measured postoperative Hct level.  A volume of 200 mL 
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per unit of pRBC transfused was used as standard for compensated RBC loss, when 
applicable. 
3.6.3 Secondary Outcome Measures 
Secondary outcome measures are defined by the investigators as areas of particular 
interest relating to, but not directly a part of the primary research question.  They are 
termed secondary not due to lack of importance, but more because of statistical 
implications relating to power calculations. The relevance of findings for secondary 
outcome measures is subject to interpretation, as the power of a well-powered RCT is 
dependent on the degree of change of the primary outcome.  However, important 
conclusions can be drawn from a study when clinically and statistically relevant 
outcomes are uncovered. 
3.6.3.1 Transfusion Rate and Adherence to Transfusion Protocol 
The goal of any blood conservation measure is to reduce the need for transfusion.  As 
part of the TeACH-R protocol, we seek to uncover a difference in the rate of transfusion 
between groups.  However, the local rate of transfusion after primary THA in 2013, 
referring to the number of patients undergoing THA at LHSC-UH needing a minimum 
transfusion of 1 unit of pRBC either intra- or postoperatively, is 4.2% (unpublished data).  
Powering a clinical trial with this as a primary outcome would require a very large 
sample size and heavy cost burden, not possible in this trial given the available funding 
opportunities.  However, it remains an important outcome measured in this study because 
of its clinical applicability.  Preoperative autologous blood donation is not considered 
part of the perioperative blood conservation protocol at LHSC-UH; a patient would be 
excluded from TeACH-R study participation if this treatment modality is part of the 
preoperative care plan. 
3.6.3.2 Complications 
Total hip arthroplasty is considered major orthopaedic surgery, carrying with it the risk of 
intra- and postoperative complications. However, when considering the addition of a new 
agent to a protocol, it is important to factor in the potential for adverse events as a result 
61 
 
of the intervention.  Table 3.5 describes the complications recorded as part of the 
TeACH-R study protocol.  These are included in our analysis were selected due to 
clinical impact; all listed events require a significant change in treatment protocol, 
possibly further surgical intervention.  Of particular interest is the incidence of venous 
thromboembolic events (VTEs) in the postoperative period, although the investigators 
expect a very low incidence given the success of the current thromboprophylactic 
regimen.  The incidence of intraoperative complications is drawn from the Operative 
Report, while postoperative in-hospital complications are noted from clinical progress 
notes and the Discharge Summary.  As mentioned in 3.5.4, postoperative complications 
are tracked up to the 3-month mark postoperatively. 
Table 3.5: TeACH-R Recorded Complications. 
Intraoperative Complications 
 Fracture 
 Acute cardiorespiratory event 
 Neurologic injury 
 Vascular injury 
Postoperative Complications 
 Venous thromboembolic event 
 Skin and soft tissue infection 
 Deep joint infection requiring revision hip surgery 
 Acute coronary syndrome 
 Acute respiratory depression  
 Acute renal failure 
 Pneumonia 
 Acute cerebrovascular accident (stroke) or transient ischemic attack 
 Wound hematoma 
 Seizure 
 Compartment syndrome 
 
3.6.3.3 Inpatient Length of Stay 
There are potential benefits associated with a shorter inpatient stay postoperatively, 
including a reduced risk of nosocomial infection91, 92 and decreased cost, both important 
factors to consider in a publicly funded health care model with limited resources.  
Because TeACH-R participants are undergoing an elective procedure requiring admission 
to hospital, comparing length of stay against the standard of care is an important metric to 
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consider when testing a new intervention that may affect the postoperative course, which 
explains its inclusion in the TeACH-R final analysis. 
 
3.7 Statistical Analysis 
Appropriate statistical analysis enables the researcher to deduce reasonable conclusions 
based on the data collected throughout the course of a study.  The TeACH-R trial is a 
prospective RCT with the goal of comparing two independent sample populations, meant 
to be representative of the population of individuals undergoing primary cementless 
THA, for a variety of nominal, ordinal and continuous variables.  The samples are 
mutually exclusive; a patient can only be enrolled in one treatment arm throughout the 
course of the study.  Data analysis follows a per protocol design, meaning that participant 
data is analyzed based on the treatment a participant receives, not to the treatment arm to 
which he or she is allocated to in the event of treatment arm crossover.  This is in 
comparison to the intention-to-treat protocol commonly used in larger clinical trials, 
meant to provide a more conservative assessment of treatment effect.  Because both 
treatment arms used in this study consist of administering a medication in a single-dose 
regimen by the treating surgeon, using the intention-to-treat protocol to decrease the 
effect of poor patient compliance is not needed in this study.  Therefore, data from a 
study participant is analyzed based on the treatment he or she has received 
intraoperatively. 
  
3.7.1 Sample Size Calculation 
Determining sample size prior to commencement of a study, especially for a randomized 
clinical trial with data collected prospectively, is of critical importance.  The concept of 
statistical power relates to the ability to decrease the chance of making a Type II error, 
and is dependent on three factors:  sample size, effect size, and level of significance.  
Sample size is a major contributor to power in that increasing sample size has the effect 
of increasing the probability of detecting a difference in outcome (if one actually exists), 
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while maintaining a defined level of significance93.  Type II errors, the acceptance of a 
false null hypothesis, are unfortunately commonplace in clinical research.  Errors in study 
methodology, data analysis and the influence of confounding factors can affect the power 
of a study.  The latter is defined as the ability to detect a difference in outcome if such a 
difference actually exists.  Best efforts must be made in order to avoid making incorrect 
conclusions about a sample population that is either not representative of the target 
population, or is not large enough to detect a statistically or clinically significant 
difference. 
For the TeACH-R trial, the sample size calculation used is shown in Figure 3.5.  This is 
the sample size calculation for an unpaired, two-tailed t test for two independent sample 
populations, based on the primary outcome variable used in this study, ΔHgb.  This 
statistical test will allow us to identify a difference in the mean ΔHgb in each of our 
treatment groups, as well as difference in calculated blood loss.  The effect size drives the 
sample size calculation.  In a previous study from LHSC-UH by Ralley et al, 
administration of intravenous TEA prior to the start of THA resulted in a significant 
reduction in ΔHgb46.  Importantly, the dosing regiment of TEA used in this study is 
identical to that used in the TeACH-R trial.  Cohen, in his 1988 book, provides a formula 
for calculating the d statistic, a measure of effect size assuming normal distribution in the 
sample, using the means and standard deviation of continuous variables.  Computing the 
results from this study into the calculation for Cohen’s results in an effect size of 0.58 
(not shown), a moderate effect size93.  Assessing effect sizes similar to this, the 
investigators determined that performing the sample size calculation with an effect size of 
0.52, as presented in Figure 3.5, would allow for a sample size large enough to be able to 
detect a clinically meaningful difference between our two treatment groups, while staying 
within the allowable margins of unavoidable logistical and financial constraints. 
In addition to effect size, other important considerations in interpreting this calculation 
include level of significance and power.  The level of significance is set at α = 0.05, the 
standard for reporting RCTs.  There is a then a 5% that the resultant outcome is due to 
chance alone, equivalent to a p value less than 0.05 as the determinant of statistical 
significance.  In a two-tailed analysis, the α level is split between the two ends of the 
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normal distribution.  We suspect, in theory, that if the topical group were to be different 
for the primary outcome of blood loss, it would be more likely deemed inferior to the 
intravenous group.  However, there is no evidence to support this judgment formed solely 
based on lack of experience in using the drug in this fashion.  While a one-tailed analysis, 
more powerful in nature, would allow us to get away with a smaller sample size, it 
implies that we have a clear idea in which direction the test treatment will differ from the 
control group.  A two-tailed analysis provides a more conservative measure of 
assessment, as the TeACH-R investigators do not know in which direction the topical 
group will differ from the intravenous group with regards to blood loss.  Statistical power 
is set at β = 0.80, implying that there is an 80% chance of identifying a difference in 
outcomes between our two independent samples, should one actually exist.  This is also 
the standard for reporting RCTs. 
 
Figure 3.5:  TeACH-R Sample Size Calculation.  *Effect size of 0.52 determined based 
on results of ΔHgb from Ralley, F et al. CORR 2010; 468: 1905-1911. 
 
This study is powered to detect a difference in the primary outcome variable, ΔHgb.  To 
put it into perspective, an effect size with a standard score of 0.52 is analogous to a ΔHgb 
of just over 6 mg/dL.  In terms of measured blood loss, this effect size corresponds to 
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approximately 300 mL of blood, using the randomized controlled trial by Johansson et al 
comparing intravenous TEA to placebo for total blood loss is as the point of reference60.  
To the TeACH-R investigators, this magnitude of difference for both variables not only 
represents a meaningful statistical difference, but also one that is clinically significant.  
Random sampling of 144 participants (or 72 per group) proceeding to THA would allows 
us to detect a clinically significant difference, should it exist, for either of our primary 
outcome measures.  Importantly, the TeACH-R trial is not powered to detect a difference 
in any of the secondary outcome measures listed in Section 3.6.3. 
The assumption of normal distribution is also important to take into consideration.  As a 
general rule, a sample size of randomly selected subjects over 30 is deemed to show a 
normal distribution for a given variable.  The stringent criteria for participant selection, in 
addition to the unbiased randomization protocol ensures that, even in this interim 
analysis, the sample drawn is representative of the population of interest, where the 
dependent primary outcome variables (ΔHgb, calculated blood loss) are assumed to 
adhere to the principle of normal distribution. 
3.7.2 Outcome Comparison 
3.7.2.1 Frequency Data 
Not all variables assessed in the TeACH-R trial are measured on a continuous scale.  
Frequency data are not amenable to analysis via traditional comparison of means.  The 
Pearson Chi-Square test is used to compare our two treatment arms when variables are 
measured at the nominal level.   In essence, it allows the comparison of observed versus 
expected frequencies, using the same level of significance of (p < 0.05) as the sample size 
calculation above.  The Chi-Square analysis, however, mandates an appropriate sample 
size for appropriate calculation of the test statistic.  If an expected frequency was less 
than 5, Fisher’s Exact Test was used to elucidate a potential difference between groups, 
again using the same level of significance.  This latter test is well known to provide more 
appropriate results when smaller samples are compared94. 
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3.7.2.2 Comparison of Means  
The foundation of the TeACH-R data analysis is in the comparison of means.  For this, 
we used a two-tailed, unpaired Student’s t test to assess for any between group 
differences for all continuous variables.  This includes both primary outcome measures.  
The Student’s t test provides a mathematically identical result to a one-way analysis of 
variance (ANOVA).  No variable was identified as having significant influence on the 
primary outcome variable; an analysis of covariance (ANCOVA) was therefore not 
appropriate for use in this study.  The probability level used for comparison is 0.05, 
where a significant difference between groups is represented by p < 0.05. 
3.7.2.3 Statistical Software 
IBM SPSS Statistics, version 22 (IBM Canada Ltd., Markham, Ontario, Canada) was 
used to perform all statistical analysis for the TeACH-R study.  
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4 Results 
 
4.1 Treatment Arm Allocation 
Figure 4.1 displays the results of randomization.  At time of interim analysis, 52 
participants had completed the initial phase of the TeACH-R protocol, meaning that they 
had received the treatment, completed a period of convalescence in hospital, and were 
discharged.  Thirty-two participants form the current cohort having received intravenous 
tranexamic acid, while 20 subjects received the topical regimen intraoperatively. 
Drawing attention to key features within Figure 4.1, a relatively high proportion of 
screened patients were excluded from TeACH-R study participation (60/120, 50%).  The 
predominant reason why screened patients were deemed ineligible for study participation 
was ineligibility to receive TEA in 21/60 (35%) of potential participants.  The most 
common reason for not being eligible to receive TEA is a prior diagnosis of DVT or PE 
(7/60, 11.6%; data not shown).  A diagnosis other than primary OA, RA or AVN 
excluded 12 of 60 (20%) of ineligible patients; most commonly, post-traumatic OA was 
the primary diagnosis (6/60, 10%; data not shown). 
Eight of sixty (13.3%) of enrolled participants withdrew from formal study participation 
after being assigned a unique TeACH-R identifier.  Data was not collected for these 
former participants.  Most often, the reason for study exclusion was a problem in 
obtaining informed consent prior to the procedure; two enrolled participants withdrew 
from the study upon entry into the OR, and in one participant consent was lost 
postoperatively.  On three occasions, a contraindication to either study participation or 
TEA administration altogether was identified only after the patient had consented to 
TeACH-R study participation. 
Forty-seven of 52 (90.4%) of enrolled TeACH-R participants received the treatment 
assigned to them via the process of randomized treatment arm allocation.  All five 
subjects who received the alternate treatment were slated to receive TEA topically, but 
instead were given TEA intravenously prior to the start of the procedure.  Interestingly, 
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three of these participants were within the first block of 20 randomized participants, with 
the other two treatment arm crossovers occurring in the second round of block 
randomization, prior to the 40th randomized participant (data not shown).  No instances of 
treatment arm crossover were recorded in the third block randomization sequence. 
 
 
Figure 4.1: TeACH-R Treatment Allocation Flow Chart. 
 
4.2 Demographics 
Table 4.1 outlines the group comparisons for the listed demographic variables collected 
as part of the TeACH-R protocol.  At baseline, the two treatment arms are similar for all 
variables. 
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Table 4.1: Demographic Characteristics for the TeACH-R Trial Sample Population. 
 
Intravenous 
Tranexamic Acid 
(n = 32) 
Topical 
Tranexamic Acid 
(n = 20) 
p value 
Mean Age, years ± SD 63.8 ± 8.7 68.2 ± 9.3 0.087 
Gender, n (%)    
 Male 17 (53.1) 7 (35.0) 
0.202 
 Female 15 (46.9) 13 (65.0) 
THA Laterality, n (%)    
 Right 18 (56.3) 12 (60) 
0.790 
 Left 14 (43.8) 8 (40) 
Mean Body Mass Index (kg/m2, ± SD) 31.2 ± 7.1 29.2 ± 6.6 0.326 
Mean Body Surface Area (m2, ± SD) 2.08 ± 0.31 1.98 ± 0.26 0.246 
Primary Diagnosis, n (%)    
 OA 31 (96.9) 19 (95%) 
0.732  RA 0 0 
 AVN 1 (3.1) 1 (5%) 
Mean Charlson Age-Comorbidity Index 3.2 ± 1.4 3.7 ± 1.0 0.249 
Mean ASA Score 2.4 ± 0.6 2.3 ± 0.5 0.368 
Type of Anaesthesia, n (%)    
 Regional (Spinal) 23 (71.9) 17 (85.0) 
0.274 
 General 9 (28.1) 3 (15.0) 
Mean Procedure Time (h:mm, ± SD) 1:08 ± 0:13 1:10 ± 0:10 0.473 
Acetabular Screw Placement, n (%) 7 (21.9) 4 (20.0) 0.872 
Mean Preoperative Hgb, mg/dl ± SD 145.09 ± 12.6 142.45 ± 11.9 0.457 
 Preoperative Anemia 3 (9.4%) 0 0.224 
Preoperative Hct, ± SD 0.432 ± 0.40 0.426 ± 0.36 0.565 
DVT Prophylaxis, n (%)    
 Factor Xa Inhibitor 31 (96.9) 20 (100) 
0.425        
 Low Molecular-Weight Heparin 1 (3.1) 0 
 
Important to note in Table 4.1 is the lack of any statistical significant difference between 
our two groups with regards to the demographic variables.  Almost all participants had a 
primary diagnosis of osteoarthritis and received rivaroxaban, a FXa inhibitor, as 
thromboembolic prophylaxis for the duration of the postoperative course.  However, at 
the time of interim analysis, the topical group had a slightly higher proportion of females 
than males, the opposite of the intravenous group.  This difference did not reach 
statistical significance.  Although both groups demonstrated similar mean scores on the 
Charlson Age-Comorbidity Index, all three participants that were anemic preoperatively 
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were allocated to the intravenous TEA group.  Although this difference did not meet 
statistical significance, it does suggest that the groups have a slight baseline difference in 
health status.  Despite the presence of these 3 anemic participants in the intravenous 
group, the mean preoperative hemoglobin level is not shown to be different between 
groups. 
 
4.3 Primary Outcome Measures 
4.3.1 Delta-Hemoglobin 
Delta-hemoglobin (ΔHgb) is defined as maximal drop in hemoglobin occurring during 
the immediate postoperative period.  The lowest measured Hgb in hospital is subtracted 
from the Hgb value drawn nearest the operative date and time to obtain this measure for 
every TeACH-R subject.  The mean of all ΔHgb values are compared between patients 
receiving intravenous and topical TEA as the primary outcome measure of the TeACH-R 
trial. 
No significant difference in mean ΔHgb between the intravenous and topical groups was 
found (34.81±13.78 mg/dL vs. 35.65±15.54 mg/dL; p = 0.840).  Given the wide error 
bars, a boxplot was used to identify any outliers that may be acting as confounders.  The 
boxplot reveals similar features for both treatment groups, with 2 minor outlying values 
and 1 major outlying value contributing to the intravenous group. 
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Figure 4.2: Postoperative Drop in Hemoglobin (ΔHgb) Following Intravenous and 
Topical Tranexamic Acid Administration in Total Hip Arthroplasty. No significant 
difference in the means of both treatment groups is identified (A), but boxplot analysis 
(B) reveals the presence of minor and major outliers within the treatment arm receiving 
intravenous TEA. 
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4.3.2 Calculated Blood Loss 
Perioperative blood loss was calculated by the method described by Rosencher, as 
described in Section 3.6.2.2 and Figure 3.4.  Mean blood loss, for all TeACH-R 
participants regardless of treatment arm allocation, was 1538 mL.  No significance 
difference in mean calculated blood loss was identified between the intravenous and 
topical TEA treatment arms (1548±509 mL vs. 1521±693 mL; p = 0.873).  Significant 
variability was noted, given the size of the error bars.  Further boxplot analysis does not 
identify any significant outliers contributing to this variability. 
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Figure 4.3: Calculated Blood Loss Following Intravenous and Topical Tranexamic 
Acid Administration in Total Hip Arthroplasty.  No significant differences in the 
means of both treatment groups (A), although both show significant variability in the 
amount of blood lost in the perioperative period (B). 
 
4.4 Secondary Outcome Variables 
4.4.1 Length of Stay 
Length of stay after THA averaged approximately 55 hours for both groups.  There was 
no significant difference between those participants having received intravenous vs. 
topical TEA (55.0±11.44 vs. 54.5±20.1 hours; p = 0.912). 
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Figure 4.4:  Length of Stay After Administration of Intravenous and Topical 
Tranexamic Acid During Total Hip Arthroplasty. 
 
4.4.2 Transfusion Outcomes 
At this time point in the TeACH-R trial, no patient in either group has required a 
transfusion of blood products during the postoperative in-hospital stay.  Consequently, 
there have been no violations in the restrictive transfusion protocol. 
4.4.3 Complications 
At this point in the process of data analysis, 4 out of 52 (7.7%) TeACH-R study 
participants have suffered perioperative complications; 2 were deemed to occur intra-
operatively, and 2 in the postoperative period.  None of these complications consisted of 
VTE.  There was no statistical difference in the incidence of perioperative adverse events 
between the intravenous and topical TEA treatment arms.  One participant having 
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received topical TEA had a questionable intraoperative fracture identified on the routine 
postoperative radiograph of the pelvis.  The weight bearing status of the participant was 
changed in the early postoperative period to protect against any component migration or 
crack propagation through the floor of the acetabulum.  Given the change in management 
required as a result of this postoperative finding, this was recorded as a complication.  
Subsequently, another patient in the topical group developed a foot drop in the early 
postoperative period.  A foot drop splint was applied and the patient was discharged with 
the diagnosis of sciatic neuropraxia.  No further surgical intervention was required.  A 
third patient in the topical group developed a significant thigh hematoma requiring close 
vigilance, but without the need for any additional treatment.  The sole complication in the 
intravenous group consisted of a deep joint infection requiring urgent irrigation and 
debridement.   
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5 General Conclusions and Discussion 
 
Interim analysis of data contained within a large-scale study is an important undertaking 
to ensure appropriate study progress.  It allows the early identification of possible 
deficiencies in data collection, management and analysis, while at the same time giving 
some perspective on preliminary outcomes.  In an RCT with a well-developed protocol, 
where the outcome data is objective and the research team responsible for data collection 
and analysis functions independent from the treating physician, minimal bias is 
introduced and valuable information can be gained by performing such an interval 
assessment of progress. 
As the TeACH-R trial approaches the midway point in the recruitment period, promising 
results arise from the preliminary analysis.  In primary elective total hip arthroplasty 
using cementless prosthetic components, the ability to decrease the postoperative 
hemoglobin drop (ΔHgb) and reduce surgical blood loss appears similar when topical 
TEA is administered by the treating surgeon directly into the joint at the end of the 
procedure, compared to the current standard of care of a weight-based dose of TEA 
administered intravenously by the attending anaesthesiologist prior to skin incision.  In 
terms of the secondary outcome measures, no statistically or clinically significant 
difference in length of stay or thromboembolic complication rate was identified between 
the two treatment groups.  Moreover, no transfusion of allogeneic pRBC was required in 
either group during the postoperative period.  Despite these findings, a conclusion of 
therapeutic equivalence or non-inferiority would be erroneous in the setting of 
preliminary data analysis, as will be discussed in the following chapter.  
 
5.1 Clinical Relevance 
Blood conservation is an important consideration in the care of the arthroplasty patient.  
As evidenced in previous chapters, TEA plays an important role the perioperative blood 
conservation protocol at LHSC-UH.  This study aims to determine whether or not TEA, 
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an antifibrinolytic agent, can be administered safely and effectively via the topical route 
at the end of THA.  Analysis of the available data set shows that topical TEA is, by all 
accounts, effective and safe when compared to the current standard of care, intravenous 
TEA, in a standard population of patients having THA.  Though there is anecdotal 
suggestion that administration of the TEA solution makes wound closure slightly more 
difficult for the deep muscle and capsule tissue layers during the time solution bathes the 
joint area, administering the drug in this manner has significant advantages. 
First, topical administration allows direct action on bleeding vessels in tissues around the 
hip joint traumatized by aggressive incision, tissue retraction, and osteotomy.  During the 
surgical approach, best attempts are made to incise through natural tissue planes to get 
down to the bone of the proximal femur.  However, in trans-muscular approaches such at 
the modified direct lateral approach to the hip, incising through muscle is unavoidable, 
risking injury to smaller vessels.  In the superficial muscular layers of the hip, cautery or 
ligation of bleeding vessels is done with relative ease; most of the time, surgical bleeding 
from these sources is identified and stopped prior to exposure of the hip joint.  More 
problematic are the deeper tissues and bony structures of the hip, incised later in the 
operation.  Surgical incision of capsular tissues around the hip during arthroplasty creates 
potential spaces able to accommodate a significant amount of blood loss in anatomic 
areas not always visible or accessible to the surgical team.  This can result in a significant 
amount of unnoticed blood loss during and after hip replacement, in addition to the 
relative inability to stop continued blood loss from raw cancellous bone.  By 
administering topical TEA into the hip joint and surrounding tissues at the end of the 
procedure, antifibrinolytic activity can be targeted onto these occult periarticular sources 
of bleeding during the postoperative period, without having to be administered 
intravenously.  As has been shown by the current results of the TeACH-R trial, this 
strategy of applying a topical antifibrinolytic appears to be relatively effective, a 
promising avenue of treatment. 
The second, and arguably more important advantage to topical administration of TEA 
relates to the theory that local administration of a drug results in concentrated activity at 
the site of application, with decreased levels of systemic absorption compared to the same 
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drug administered intravenously.  Reliance on diffusion of TEA from the intravascular 
compartment to the joint space is less effective than applying the drug directly to the 
joint, the source of a significant amount of postoperative bleeding in arthroplasty-related 
procedures.  It has been determined, in studies where TEA used to counter the fibrinolytic 
response after cardiopulmonary bypass, that TEA follows a two-compartment model of 
distribution95, 38.  In simple terms, diffusion into and elimination from a compartment is 
dependent on transfer constants related to the permeability of the tissues and the physical 
characteristics of the substance.  For the purpose of TEA use in total joint arthroplasty, 
this implies an unpredictable concentration of TEA within the operative joint when the 
drug is administered intravenously.  Administration of the same drug topically means that 
the drug is not dependent on diffusion into the joint to be able to exert its action where it 
is needed the most, at a concentration that is predictable. 
In addition to its effect on blood loss, there is concern that TEA has the ability to stabilize 
clots at sites distant to the surgical wound, increasing the risk of thromboembolic events 
when used in arthroplasty-related procedures.  Thus far in the TeACH-R trial, no 
participant has been diagnosed with either a deep vein thrombus or pulmonary embolism, 
which is reassuring.  Best efforts are made to balance clinical efficacy and systemic load 
for TEA, even though robust meta-analysis data has never proven an increased risk of 
thromboembolic complications resulting from TEA administration in THA.  In addition 
to this postulated risk, there has also been suggestion of increased seizure activity when 
TEA is administered intravenously at a higher dose, further emphasizing the need for 
development of protocols that administer the correct dose for a particular patient, using 
the correct route of administration, for fear of causing side effects with administration of 
a toxic dose.  Though there are few studies that have defined the absorption profile when 
TEA in given in THA, we can extrapolate a significant amount of information about the 
pharmacokinetic properties of TEA from the aforementioned studies in cardiac surgery, 
as well as from the study by Wong et al, who quantified plasma TEA levels after topical 
administration of the drug in TKA39.  Thanks to these studies, we know there is some 
truth for TEA administered locally at the surgical site having significantly less systemic 
absorption than the intravenous form of the same drug, and that increasing the dose of a 
local TEA does not always parallel the expected clinical benefit.  At the very least, our 
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results show that at a dose analogous to that used for intra-articular administration in 
TKA, clinical efficacy of topical TEA appears to be comparable to that afforded by 
intravenous TEA, without an increase in thromboembolic complications.  We would 
expect the systemic load of TEA of our topical treatment arm to be similar to the 1.5-
gram intravenous TEA arm of the Wong study, although we do not currently have the 
data to support this claim. 
Despite these theoretical risks, intravenous TEA remains a valuable adjunct in our 
perioperative blood conservation protocol for patients having THA and TKA.  At LHSC-
UH, it is widely regarded as a safe drug when given to the right patient.  Since its 
inception as standard of care for perioperative blood conservation in lower extremity joint 
arthroplasty at LHSC-UH, the influence of intravenous TEA in the arthroplasty patient 
population has resulted in improved surgical outcomes, including but not limited to lower 
ΔHgb and postoperative transfusion rates, with minimal downside.  A large part of this 
success is due to the stringent preoperative medical review performed by not only the 
surgical team, but also by the clinicians working within the Perioperative Blood 
Conservation Program. 
An important issue that remains to be determined is precisely who can receive 
intravenous TEA, topical TEA, or neither.  Interim analysis of the TeACH-R trial has 
shown that a significant proportion (35%) of patients having elective primary THA have 
a documented contraindication to receiving intravenous TEA as per the TeACH-R 
protocol, and are not able to benefit from the drug.  It is possible that some of these 
patients not eligible for intravenous TEA could benefit from topical TEA, if a decreased 
systemic load can be proven with the latter form of treatment.  There just simply is not 
enough guidance available in the literature to support giving TEA to these patients 
deemed to have an elevated risk of adverse events, even though there may not be any 
absolute contraindication present within the medical history.  Admittedly, given the novel 
application of topical TEA in THA for the TeACH-R trial, the exclusion criteria for this 
study are decidedly conservative, seeking to enroll participants who fit the medical 
profile of the standard arthroplasty patient, without any overt contraindications to TEA 
administration.  Further investigation into the potential benefit of administering topical 
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TEA in a more liberal fashion could be warranted, but this is ultimately dependent on the 
final analysis of the TeACH-R trial, which will only be available once the predicted 
sample size of 144 participants is achieved. 
For the majority of THA patients that can take the drug, weight-based intravenous 
administration will likely remain a mainstay of therapy, even with the promising 
outcomes that have come in this interim analysis.  The single-dose TEA protocol has 
been well received by both surgeons and anaesthesiologists alike, not only because of the 
significant clinical benefit, but also due to the relative ease of use.  The process of formal 
adoption of a novel form of therapy is dependent not only on the results of high-quality 
RCTs, but also on surgeon preference.  However, it will be interesting to re-assess the 
results once all data has been collected, in order to determine whether or not these 
preliminary outcomes hold true once statistical power is reached for our sample 
population.  If they do, there may be a role of topical TEA as an alternate to intravenous 
TEA for select patients undergoing THA. 
 
5.2 TeACH-R Trial Analysis and Design 
Commonly, an RCT seeks to determine superiority over the accepted standard of care 
beyond a reasonable doubt.  This reasonable doubt, in statistical terms, is the level of 
significance.  When there is no standard of care, determination of superiority over no 
treatment, or placebo, provides the impetus for a change in the standard of care.  
Importantly, acceptance of the null hypothesis for a superiority trial is not to be confused 
with therapeutic equivalence; after all, as the statistical axiom stipulates, absence of 
evidence does not equal evidence of absence.94  
In certain circumstances, a form of treatment exists that is widely accepted as the 
standard of care for the population under study.  If a study participant is eligible to 
receive the standard of care, but is assigned to the placebo arm of the study, serious 
ethical implications arise due to withholding treatment with known benefit.  At LHSC-
UH, a patient undergoing THA that is able to safely receive TEA intravenously based on 
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their preoperative risk profile will receive the drug as standard of care.  However, topical 
administration of TEA has postulated benefits: decreased systemic absorption and local 
action on bleeding vessels are generally desired characteristics of a drug administered to 
stop surgical bleeding.  The goal of the TeACH-R RCT is to determine whether our test 
group, participants receiving topical TEA, show a difference with regards to blood loss 
compared to the active agent acting as the standard of care, intravenous TEA. 
Initially, the investigators favored a non-inferiority trial design, where the goal is not to 
prove superiority, but instead to determine whether topical TEA is inferior to intravenous 
TEA with regards to blood loss in THA.  However, clinical trials of this variety depend 
on the rate of an event occurring, in order to determine the odds ratio of said event 
occurring when the novel treatment is given compared to the standard of care.  In the end, 
we wish to determine the net benefit of the new treatment, defined as the absolute risk 
difference.  ΔHgb, a continuous measure, is not amenable to determination of risk 
reduction.  Clinically important event rates for the TeACH-R trial would include the 
incidence of postoperative transfusion, or the incidence of thromboembolic phenomena 
as a consequence of treatment in either arm.  With the advances in patient care that have 
come about in the field of orthopaedic surgery, as well as a renewed focus on the medical 
care of the orthopaedic patient, these adverse events are a relative rarity.  The sample size 
required to prove a marginal clinical benefit for these variables is unfortunately beyond 
the limits of the available resources for the TeACH-R study. 
The ΔHgb and calculated blood loss, on the other hand, provide sensitive parameters to 
test our hypothesis, with the requirement of far fewer patients in each of our treatment 
arms.  Between-group differences in these primary outcome measures also have the 
potential to change management, should the results reach clinical significance.  In this 
interim analysis, we get the initial impression that topical TEA has the potential to be an 
efficacious alternative to intravenous TEA for reduction of blood loss in patients having 
primary THA, for both aforementioned variables, with little risk of adverse events.  
However, caution must be taken in interpreting these interim results, as statistical power 
has yet to be achieved for our sample population. 
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5.3 Strengths of the TeACH-R Study 
Results emanating from the TeACH-R trial will contribute significantly to understanding 
the role and importance of perioperative blood conservation in the arthroplasty patient.  
With the gradual increase in use of TEA as a valuable adjunct to perioperative blood 
conservation programs, high quality RCTs will become paramount in supporting or 
refuting novel therapeutic regimens for TEA.  Unfortunately, there are a great number of 
clinical trials on the topic, although few are of high-enough quality to effectively change 
management.  Although a significant number of trials have shown promise when TEA is 
given in THA, the variety of treatment protocols makes it difficult to deduce which route 
of administration is more effective as an adjunct in controlling perioperative blood loss.  
This study will clarify how TEA can be administered most effectively for the patient 
having elective primary THA. 
The TeACH-R trial is the first and only RCT designed as a direct comparison between 
topical and intravenous TEA in THA. There is supportive evidence for using both topical 
and intravenous TEA from studies assessing each form of treatment independent of the 
other, in placebo-controlled trials, but never have these two treatment alternatives been 
compared directly for these primary and secondary outcomes.  In the quest to find the 
right form of TEA with optimal dosing, comparing all available modalities not only to 
placebo, but also to one another is an important step in determining which treatment is 
the standard of care for a given population. 
Our sample size of 144 participants is powered to detect a clinically significant difference 
for two important primary outcomes: the drop in Hgb after hip replacement, and total 
blood loss. The assessment of blood loss has traditionally been measured by imperfect 
means, and unfortunately these results have permeated the literature surrounding this 
topic, often resulting in a significant underestimation of the magnitude of blood loss.  The 
TeACH-R trial protocol uses a robust formula for calculating blood loss using proven 
research methodology to get the most reliable estimate, further increasing the validity of 
the treatment comparison.  Furthermore, the large sample size helps in decreasing 
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variability in our results, and ensures a normal distribution for the continuous variables 
studied. 
The well-developed prospective study design of this trial also strengthens the validity of 
the results by minimizing bias due to errors in study methodology.  The stringent 
TeACH-R protocol ensures that randomization and blinding are maintained throughout 
the duration of the study.  In combination with the objective nature of the data collected, 
there are few sources of bias even with a single-blinded protocol.  The stringent inclusion 
and exclusion criteria for the TeACH-R trial isolate the population representative of the 
majority of patients proceeding to THA for whom perioperative administration of TEA is 
indicated. 
 
5.4 Limitations of the TeACH-R Study 
The predominant limitation at this point in time is the size of the available data set.  We 
have reached a sample size that allows comparison of the means for certain variables 
between the treatment arms on the basis of a normal distribution, but have not yet reached 
the size necessary to affirm our conclusions.  In the end, our current sample is similar to 
the target population under study, but the ability to detect a statistically significant 
difference in each of our primary outcome variables is limited by the number of 
participants in each of our sample group.  However, recruitment is proceeding well, and 
given that LHSC-UH is a high-volume Canadian center for total joint arthroplasty, it will 
not be long before data is available for the final analysis. 
The TeACH-R study is not powered to identify any significant difference in any of our 
secondary outcome measures, given the infrequent nature of occurrence for these 
variables.  Even though these outcomes are important, the sample size that would be 
required for detect a clinically significant difference for these variable is not possible 
given resource limitations. 
Another important consideration is that the TeACH-R study does not have a placebo 
control group.  As mentioned previously, when a treatment exists that is considered 
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standard of care, like is the case with intravenous TEA in THA at LHSC-UH, is becomes 
unethical to enroll a study subject in a placebo-controlled RCT when he or she would 
otherwise be eligible to receive the standard of care.  Thankfully, data from the TRANX-
H trial, published in 2013 with similar study methodology and outcome variables to the 
TeACH-R trial, showed that administration of topical TEA was indeed superior to 
placebo for blood loss and transfusion rate reduction in THA,56 in addition to the number 
of studies that have shown benefit of intravenous TEA in THA for the same outcome 
variables.  Early in the study development phase, there was consideration for an 
additional treatment arm where TEA would be applied earlier in the procedure at time of 
arthrotomy, instead of at the end of the procedure when the arthrotomy was closed.  
Amongst the arthroplasty surgeons at LHSC-UH that would be participating in this trial, 
it was felt that administering TEA at this time, with the mandatory 5-minute pause, would 
create an undue surgical delay with minimal perceived benefit.  While not considered a 
limitation per se, the addition of this treatment arm would have provided relevant data 
with regards to timing of topical TEA administration.  In all, the comparison between the 
two treatment arms in the TeACH-R study represents reliable and valid study 
methodology, even without a placebo group. 
 
5.5 Final Remarks and Further Developments 
Early in the study development phase, The TeACH-R investigators asked a research 
question: is topical TEA, administered directly into the hip joint, as effective at reducing 
blood loss compared to intravenous TEA?  This simple question led to the development 
of a significant research endeavor that has shown significant progress in the twelve 
months since its inception. 
The purported benefits of topical TEA are not only related to improved control of blood 
loss over intravenous TEA, but also on decreasing the potential complications that arise 
from administration of intravenous TEA.  At the very least, we strive to ensure that this 
novel form of treatment is not inferior to the standard of care with regards to blood loss.  
At the time of interim analysis, the delivery of TEA topically at the time of arthrotomy 
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closure shows similar clinical benefits with regards to perioperative blood loss when 
compared to intravenous TEA in THA.  Very few adverse events have been identified, 
with no difference between the two treatment arms of the TeACH-R trial for all the 
variables examined.  Should the final analysis show similar findings once the sample size 
is large enough for the study to be adequately powered for the primary outcomes of ΔHgb 
and calculated blood loss, topical TEA could potentially play a significant role as a 
valuable adjunct for perioperative blood management in patients going for THA, in 
addition to the current standard of care, intravenous TEA.  
Future developments are focused on defining the safety profile of TEA, beginning with 
the analysis of plasma TEA levels in patients receiving either topical or intravenous TEA 
during THA.  This will allow further delineation of safe treatment regimens, and provide 
insight into the pharmacokinetic properties of TEA when used at the typical doses for 
perioperative blood conservation in THA. 
In all, evidence from the interim analysis of the TeACH-R trial, supported by data from 
other studies, suggests that TEA administered both intravenously and topically can 
provide significant benefit to patients undergoing THA, all the while maintaining a 
favorable risk profile.  Although much work has yet to be done in uncovering the 
intricacies in administering this antifibrinolytic agent safely, exciting opportunities 
certainly exist for further development in the field of perioperative blood conservation for 
arthroplasty patients.  Exploring the clinical efficacy of alternative therapies like these 
could usher in a new way of helping the thousands of individuals who proceed to THA 
each day in Canada and across the world. 
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Appendix A:  List of Abbreviations 
Apr Aprotinin 
ANOVA Analysis of variance 
ASA American Society of Anaesthesiologists 
BUN Blood Urea Nitrogen 
CBC Complete blood count 
Cr Creatinine 
DDH Developmental dysplasia of the hip 
DTI Direct thrombin inhibitor 
DVT Deep vein thrombosis 
ΕACA Epsilon-aminocaproic acid 
ESA Erythropoietin-stimulating agent 
FVII(a) Factor VII (activated) 
FX(a) Factor X (activated) 
FXaI Factor Xa inhibitor 
FXIII(a) Factor XIII (activated) 
Hct Hematocrit 
Hgb Hemoglobin 
IA Intra-articular 
INR International Normalized Ratio 
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IT Ilio-tibial 
IV Intravenous 
LCPD Legg-Calvé-Perthes disease 
LHSC-UH London Health Sciences Centre, University Hospital 
LMWH Low-molecular-weight heparin 
OA Osteoarthritis 
ONP Orthopaedic Nurse Practitioner 
OR Operating Room 
PAC Pre-Admission Clinic 
PBCP Perioperative Blood Conservation Program 
PE Pulmonary embolus 
pRBC Packed red blood cells 
PTT Partial thromboplastin time 
RA Rheumatoid arthritis 
RCT Randomized controlled trial 
SCFE Slipped capital femoral epiphysis 
TEA Tranexamic acid 
TeACH-R Tranexamic Acid Comparison in Hip Replacement (Trial) 
TF Tissue Factor 
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THA Total hip arthroplasty 
TKA Total knee arthroplasty 
UFH Unfractionated heparin 
VTE Venous thromboembolic event 
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Appendix C:  TeACH-R Consent Form 
 
Comparative Efficacy of Topical versus Intravenous Administration of 
Tranexamic Acid in Primary Total Hip Arthroplasty  
 
Study Doctors           
Dr. Douglas Naudie – London Health Science Centre   
Dr. James Howard – London Health Science Center                          
Dr. Fiona Ralley – London Health Sciences Centre 
Dr. Lyndsay Somerville – Sandy Kirkley Centre for Musculoskeletal Research 
Dr. Richard Nadeau – Orthopaedic Surgery Resident 
Study Coordinators 
Katherine Hrabok       
Abigail Korczak        
 
Dear Patient: 
 
You are being invited to voluntarily participate in a research study designed for patients 
undergoing a total hip replacement. This letter of information describes the research 
study and your role as a participant. Please read this letter carefully. Do not hesitate to 
ask anything about the information provided. Your doctor or nurse will describe the study 
and answer your questions.  
 
Purpose 
 
The rationale for this project focuses on preventing bleeding in total hip replacement 
surgery.  The ability to stop bleeding is of concern to the surgeon, as joint replacement 
carries a high risk of complications when significant bleeding happens.  Albeit necessary 
at times, and generally deemed safe, your surgical team is looking to decrease the rate of 
transfusion of blood products after your hip replacement.   
 
Tranexamic acid is a drug that has received lots of attention recently, as it helps to reduce 
post-operative bleeding.  In total knee replacement, a tourniquet around the leg can be 
used to control  bleeding; this is not possible when your surgeon is operating on your hip.  
Currently at LHSC, tranexamic acid is administered in its intravenous (IV) form to most 
patients undergoing joint replacement.  Your anaesthetist would give you this drug prior 
to the start of the operation.   This same drug placed directly into the joint (termed 
‘topical’ administration) at the end of the procedure may also be beneficial; giving it this 
way allows for direct action of the drug on sites of bleeding.  Compared to the IV route, 
there is less of the drug absorbed throughout the rest of the body.  To date, no studies 
have directly compared IV versus topical administration of tranexamic acid in hip 
replacement surgery in terms of either safety or effectiveness. 
 
This study is designed to compare the two methods of administering tranexamic acid in 
patients who receive a total hip replacement.  The two groups studied are as follows: 
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1. One group will receive the intravenous form of tranexamic acid, administered 
prior to the start of the procedure.  This is the standard protocol for joint 
replacement at University Hospital. 
2. The second group will receive the topical form of tranexamic acid, to be 
infiltrated as a sterile solution directly into the hip joint once the implants are 
secured into the bone.  It will be kept in for 5 minutes while your orthopaedic 
surgeon finishes the operation. 
 
In order to provide further insight into the absorption of tranexamic acid, we will also 
collect one additional blood sample within one hour of administration of the drug, in both 
groups, to measure levels of tranexamic acid in the blood stream.  All other blood 
samples will be drawn as per the standard hip replacement pathway.  The investigators 
will collect data indicative of post-operative bleeding and any complication that arises 
during your stay in hospital. 
 
The results from this study may help researchers improve blood conservation strategies 
for hip replacement surgery in the future.  The main purpose of this study is to determine 
which route of administration provides the safest and most effective way of delivering 
tranexamic acid during hip surgery.  If no difference is seen, the current standard of care, 
which is to administer the drug intravenously prior to the procedure, will continue to be 
utilized. 
 
Approximately 144 patients from London Health Sciences Centre will participate. 
 
Procedure 
 
Should you meet the study criteria and wish to participate, you will be randomly 
assigned, like a flip of a coin, to one of the two groups.  You will not know what group 
you are in.  All patients will continue to receive the same level of care in the time leading 
up to, during, and after surgery. 
 
Either during surgery, or while you are recovering from surgery, a health care 
professional will collect a blood sample to be sent for tranexamic levels. 
 
After your surgery, the investigators will monitor your progress in hospital by reviewing 
your medical chart.  Only data relevant to the study will be collected from your chart.  A 
de-identification process ensures that only the study investigators will be able to link the 
health information contained in the chart with your personal information.  The care 
providers that follow your progress after hip surgery will not be aware which study group 
you are in, and will not be able to answer questions related to the study.  There will be no 
information present within your chart that tells the nurses and allied care professionals for 
of the drug you have received.  However, the surgeon and residents caring for you while 
in hospital may be aware of which group you are randomized to, and are given strict 
instruction not to discuss the study or divulge any study-related information.  They will 
determine whether you will need a blood transfusion, and will manage any medical issues 
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that arise while you are in hospital.  There will be no difference in your hip replacement, 
physiotherapy or nursing care after surgery.  
 
Study Risks  
 
By participating in this study, you are at no increased risk compared to current standard 
of care in total hip replacement surgery. 
 
As your medical chart will be reviewed, an infringement on your privacy may occur. 
Your individual results will be held in confidence. No person, other than your doctor, 
nurses and the study team will have access to your study-related records without your 
permission. 
   
During the course of the study you will be informed of any significant new finding (either 
good or bad), such as changes in the risks or benefits resulting from participation in the 
study or new alternatives to participations that might change your decision to continue 
participating in this study. If new information is provided to you, your written consent to 
continue participating in this study will be requested. 
Study Benefits 
 
You may or may not benefit directly from participation in this study. The results of this 
study may be of benefit by helping surgeons discover new ways to reduce blood loss 
during hip surgery. 
 
Voluntary Participation 
 
Participation in the study is voluntary. You may refuse to participate, refuse to answer 
any questions or withdraw from the study at anytime with no effect on your future care. 
You do not waive any legal right  
by signing the consent form.  There is a process of de-identifying your personal health 
information from the data collected in the study.  Be aware that once data has been de-
identified it will become impossible to have your data withdrawn from the study. 
 
Alternatives to Study Participation 
 
You will receive standard medical care by your doctor if you choose not to participate in 
this study. If you decide not to participate in this study, your surgeon and 
anaesthesiologist will determine whether or not you will receive tranexamic acid during 
your surgery.  You do not have to participate in this study in order to have your hip 
replacement surgery. 
 
Confidentiality 
 
You will not be identified personally in any publication or communication resulting from 
this study. All  
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information collected will be stored in a locked office and entered into a secure database, 
accessible by authorized individuals only. Your identifiable information, such as your 
name, hospital identification number and surgery date, will be held separately from the 
other information collected and will be only linked by a study ID number. This 
information will be used solely for the advancement of medical science and any personal 
information will be kept confidential. A copy of this letter will be given to you.  
 
Representatives of the University of Western Ontario Health Sciences Research Ethics 
Board may  
contact you or require access to your study-related records to monitor the conduct of the 
research. 
If you have any questions about your rights as a research participant or the conduct of the 
study you may contact Dr. David Hill, Scientific Director, Lawson Health Research 
Institute 519-667-6649. 
 
If you have any questions about this study or your care please contact Katherine Hrabok, 
Clinical Research Coordinator, Department of Orthopaedics, London Health Sciences 
Center – University Hospital, or Dr. Jamie Howard, primary study investigator and 
Orthopaedic Surgeon at London Health Sciences Center.  
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Comparative Efficacy of Topical versus Intravenous Administration of 
Tranexamic Acid in Primary Total Hip Arthroplasty 
 
 
Informed Patient Consent 
 
 
Agreement of Participating Subject 
 
I have read the letter of information, have had the nature of the study explained to me, 
and I agree to participate.  All questions have been answered to my satisfaction. 
 
 
 
Print Participant’s full name 
 
 
 
Participant’s signature  Date        Date 
 
 
 
Name of person obtaining consent 
 
 
 
Signature of person obtaining consent  Date    Date 
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Appendix D:  Medical Directive for Tranexamic Acid 
 
SRG-2010-003 
 
 
 
 
Medical Directive 
Title: 
Preoperative Written Order for Tranexamic Acid (TA) in 
Orthopedic Surgery 
Lead Contact Person: Donna Berta, PBCP Coordinator 
Program: Surgery / Anesthesia and Perioperative Medicine 
Approval By: Medical Advisory Committee 
Original Effective 
Date:  
 
Revised Date: 
 
Reviewed Date: 
 
This Medical Directive Applies to:   All LHSC sites   or  
 
 LHSC-UH   LHSC-VH    LHSC-SSH                                                                                                              
 
 
Order: 
      Knee surgery: 
           Send to Surgical Prep Unit                                                                                                                                            
           Tranexamic acid * mg (wt ** kg), in 50 mL 0.9 % sodium chloride IV, administer at 
patellar clamping                                                  
            v/o Dr. F. Ralley/_____ PBCP RN  
 
       Hip surgery:   
           Send to Surgical Prep Unit   
           Tranexamic acid * mg (wt **kg), in 50 mL 0.9 % sodium chloride IV, administer 10 
minutes prior to  
           skin incision 
           v/o Dr. F. Ralley/_____ PBCP RN 
 
*    dose of TA based on table Tranexamic Acid order per Patient Weight Increment (see 
Appendix 2)  
**  patient’s weight measured at Preadmission Clinic assessment or estimate if patient 
unable to weight  
     bear 
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Appendix Attached?   Yes   No 
 
Recipient Patients: 
University Hospital Orthopedic Surgery patients of Drs. Bourne, Howard, MacDonald, 
McAuley, McCalden, and Naudie assessed via Preadmission Clinic undergoing elective 
surgical procedures  
• unicompartmental, primary, bilateral, revision knee joint replacement  
• primary, bilateral, revision hip joint replacement 
• periacetabular and femoral osteotomy and open surgical dislocation hip surgery 
 
Authorized Implementers: 
 
Position / Title Qualifications / Certifications 
Registered Nurse RN in the Blood Conservation 
Program 
 
 
 
Indications & Contraindications: 
Indications:  
1. All University Hospital Orthopedic Surgery patients assessed via Preadmission Clinic 
undergoing elective surgical procedures (procedures as listed Recipient Patients) 
provided the patient has absolutely no history of previous thrombotic vascular event 
(TVE) 
2. For University Hospital Orthopedic Surgery patients assessed via Preadmission Clinic 
undergoing elective orthopedic surgical procedures not listed in Recipient Patients, if 
the PBCP nurse believes TA might be indicated, she may contact the attending 
Orthopedic Surgeon for direction regarding potential implementation of intra-operative 
TA  
 
Relative Contraindications: 
1. The PBCP Nurse will consult the PBCP Director or their designate regarding patients 
with history of TVE. The PBCP Director or designate will review such patients to assess 
the patient specific risk/benefit profile and advise the PBCP nurse if TA is to be ordered 
or not.  
2. The PBCP Nurse will consult the PBCP Director or their designate regarding patients 
with drug eluting stents to treat coronary artery disease within the previous 2 years and 
ongoing Plavix treatment. The PBCP Director or designate will review such patients to 
assess the patient specific risk/benefit profile and advise the PBCP nurse if TA is to be 
ordered or not. 
 
• Absolute Contraindications:  
1.  Patients with history of TVE in previous 12 months or requiring life long 
anticoagulation related to previous TVE  
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Medication / Drug Table:  
 
Drug 
Name 
(GENERIC 
only) 
Route of 
Administration 
& Dosage 
Range 
Indication Absolute 
Contraindications 
Considerations 
for Dosage 
adjustment 
(e.g. Renal or 
hepatic) 
Special 
Monitoring 
Requirements 
(i.e. lab tests) 
Tranexamic 
Acid  
Intravenous in 
50 mL 0.9 % 
sodium chloride 
minibag 
See Appendix 2 
regarding 
dosage range 
Administered 
intraoperatively 
by Attending 
Anesthesiologist 
To 
decrease 
surgical 
blood loss 
in 
orthopedic 
knee and 
hip joint 
surgery 
Patients with 
history of  TVE in 
previous 12 
months or 
requiring life long 
anticoagulation 
related to previous 
TVE  
 
none none 
Reference:  
1. Compendium of Pharmaceuticals and Specialties. Canadian Pharmacists Association, 
Ottawa 2007:    
    Cyklokapron, 649.  
2. LHSC intranet Parenteral Drug Administration Manual 
    http://www.lhsc.on.ca/priv/monograph/Of8olI6eAhQAABlCTNE.htm 
 
Consent: 
• Attending Orthopedic Surgeon who obtains the surgical procedure consent, also 
obtains consent for blood and blood products and any alternatives (Form #8460-
5645 revised 2008)  
 
Educational Requirements 
Information or educational requirements to guide practice include: 
• Minimum of 5 years recent clinical experience in surgical patient care 
• Completion of ONTraC blood conservation orientation program 
• Ongoing participation in ONTraC program continuing education 
 
Appendix attached?  Yes   No 
Documentation & Communication: 
• PBCP assessment, consultation with PBCP Director or their designate, plan of care 
and treatment implemented is documented on the patient’s Health Record utilizing 
Perioperative Blood Conservation Program form (NSR5080 revised 2009).  
• Written order for TA is documented on the LHSC Patient Care Order form (8460-
5602 revised 2009) 
 
Review and Quality Monitoring Guideline: 
• For this Medical Directive TVE is defined as: stroke, transient ischemic attack, deep 
vein thrombosis, pulmonary embolism 
• The PBCP director or their designate will be contacted via email (as per LHSC 
Electronic Mail Use Policy INT 006) regarding patients with history of TVE. The 
PBCP Director or designate will review such patients to assess the patient specific 
risk/benefit profile and will reply by email to advise the PBCP nurse if TA is to be 
ordered or not.                                                                                                              
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In situations of limited pre-operative time frame, telephone communication will occur 
• All University Hospital Orthopedic Surgeons track their own patient TVE incidents; 
frequency of TVE incidents is reviewed semi-annually at Orthopedic Surgeons 
Division meeting.  Dr. D. Naudie, Orthopedic Surgeon and PBCP Committee 
member will advise PBCP Director or their designate of any increase in frequency of 
such incidents  
• Blood transfusion rates for University Hospital Orthopedic Surgery procedures are 
reported semi annually to the PBCP Director and to Orthopedic Surgeons by Donna 
Berta, PBCP Coordinator 
 
Professional Staff Approvals (Physician, Dentist, Midwife): 
• Identify all Professional Staff members (<10 list by individual name, >10 list by 
title & program) responsible for patients who may receive an order or 
procedure under this medical directive.  
 
NAME DEPARTMENT / PROGRAM 
Dr. Fiona Ralley 
 
Director, PBCP 
Dr. Ian Chin-Yee 
 
Hematologist, PBCP  
Dr. Cyrus Hsia 
 
Hematologist, PBCP 
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SRG-2010-003 
 
 
Administrative Authorization Approval Form 
 
Please note:  signature pages are not to be signed until the medical directive has 
been approved.  
 
Medical Directive:  Preoperative Written Order for Tranexamic Acid (TA) in 
Orthopedic Surgery  
 
Lead Contact Person (s): Donna Berta, PBCP Coordinator 
 
Administrative Authorizations 
(approved by): Signature 
Date 
Chair, LHSC Medical Advisory 
Committee / Dr. Christopher 
Fernandes 
 
  
Chair, Drug & Therapeutics 
Committee / Dr. David Massel 
 
  
Director, Perioperative Blood 
Conservation Program / Dr. 
Fiona Ralley 
 
   
Hematologist, Perioperative 
Blood Conservation Program / 
Dr. Ian Chin-Yee 
 
  
City-Wide Chair-Chief 
Anesthesia & Perioperative 
Medicine / Dr. Davy Cheng 
 
  
Anesthesia Site Chief – 
University Hospital / Dr. Chris 
Harle 
 
  
Orthopedic Surgery Division 
Chief / Dr. James Roth 
 
  
Surgery Site Chief – University 
Hospital / Dr. Steven J. 
MacDonald 
 
  
Director, Surgical Care Program 
/ Ms. Carol Rhiger 
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Nursing Professional Practice / 
Kathleen Ledoux, or delegate 
 
  
Implemented by: 
(Person(s) performing 
initiation or person 
representing a large group and 
responsible for notification of 
that group) 
Signature Date 
Donna Berta, PBCP Coordinator 
 
  
Valerie Binns, PBC Coordinator 
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